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ABSTRACT
The Association of Demographics, Social and Personal/Family Characteristics with Treatment
Utilization Among Young Adults with Opioid Use Disorder in the United States
by
Marva Leonora Frederick, MSN, MA, RN
Advisor: Dr. Linda Scheetz
Background
Opioid use disorder is a life-threatening medical condition and an ongoing public health
problem in the United States. Treatment is necessary to combat opioid use disorder and to
minimize the health-associated problems. Opioid use disorder is treatable with life-extending
medications. Studies that examined treatment utilization among young adults with opioid use
disorder in the United States was scarce. This study investigated the characteristics posited in
the Andersen Behavioral Model of health utilization which may be associated with treatment
utilization, among young adults with opioid use disorder in the United States. The urgency
posed by the continuing opioid crisis in the United States underscores the timeliness of this
study. The research question was: What is
the predisposing, enabling, and needs characteristics as posited in the Andersen
Behavioral Model that are significantly associated with treatment utilization among young adults
with opioid use disorder in the United States?
Theoretical Framework
The Andersen Behavioral Model of health utilization guided the study. The Andersen
Behavioral Model posited multiple population characteristics which may be associated with
treatment utilization.
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Methods
A secondary analysis of the 2017 National Survey on Drug Use and Health dataset was
conducted. Records of young adults with a diagnosis of opioid use disorder (n = 1,021) were
filtered from the secondary dataset. A dichotomous variable in the dataset, treatment utilization,
served as the outcome variable. Covariates were derived from the predisposing, enabling and
needs characteristics posited in the Andersen Behavioral Model, and available in the secondary
dataset. A hierarchical binary logistic regression model was used to analyze the association
between potential covariates and treatment utilization for opioid use disorder.
Results
The most concerning finding was that more than 90% of this study’s sample did not
utilize treatment. Further, young adults were more likely to utilize treatment if they had an arrest
history. Significant associations were observed with the predisposing characteristics
race/ethnicity, employment status, and household size.
Conclusion
To plan effectively and comprehensively, and to formulate strategies for enhancing
opioid use disorder treatment utilization among young adults in the United States, it may be
necessary to fully explore the population characteristic arrest history, in addition to other
significant associations reported. Existing treatment strategies should be assessed to determine
their usefulness and efficiency.
Keywords: opioid use disorder, treatment utilization, young adults, Andersen Behavioral
Model, logistic regression
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Chapter 1: Background and Study’s Purpose
Background and Problem
Results from the National Survey on Drug Use and Health (NSDUH) revealed that young
adults in the U.S. had a greater prevalence of substance use compared to older adults in the years
2016 and 2017 (Ahrnsbak, et al., 2017; Bose, et al., 2017, 2018). The difference in prevalence
between the two years had changed minimally. One in seven young adults or 5.3 million
(15.5%) was reported as needing substance use treatment in 2016. In 2017, the number of young
adults needing substance use treatment remained at one in seven or 5.2 million (15.1%).
Conversely, older adults needing substance use treatment in 2016 was reported at 14.5 million
(6.9%) compared to 14.5 million (6.8%) in 2017. Consistent with previous research, needing
substance use treatment in this study was interpreted as having a substance use disorder (SUD)
or having received substance use treatment in the past year (Bose, et al., 2017; Lipari, et al.,
2016). SUD in the 2017 NSDUH dataset, was based on the diagnostic criteria for substance
dependence/abuse specified in the Diagnostic and Statistical Manual of Mental Disorders IV
(DSM-IV; American Psychiatric Association, 1994), as shown in Tables 1 and 2. SUDs
encompass alcohol use disorder (AUD) and drug use disorder relating to misuse of prescription
opioids, stimulants, sedatives, inhalants or use of methamphetamine, tranquilizers, marijuana,
cocaine (including crack), hallucinogens, heroin (Park-Lee, et al., 2017; Substance Abuse and
Mental Health Service Administration [SAMHSA], 2018d). Opioid use disorder (OUD) was
classified by NSDUH as an individual meeting the DSM-IV criteria for pain reliever use disorder
and/or heroin use disorder in the past year (Bose, et al., 2017, 2018; SAMHSA, 2018d). This
study focused on OUD (a subtype of SUD) among young adults. Young adults were classified as
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an individual 18 - 25 years old. An older adult referred to an individual > 25 years and an
adolescent was an individual 12 - 17 years old.
Table 1
Criteria for Substance Abuse (excludes alcohol) Based on DSM-IV Criteria: One or More
Occurring Within a One-Year Period

Criteria for Substance Dependence (excludes alcohol)
- Based on DSM-IV Criteria: Three or More
Occurring Within a One-Year Period

• tolerance due to (a) a need for
substance
increased amounts of the substance, or (b)
continued use of the same amount with
diminished effect
characteristic
• 3 withdrawal syndrome for the
substance, or the same (or closely related)
substance was
3 taken to relieve or avoid
withdrawal symptoms
3
taking a •substance
in larger amounts or over
3
a longer period than intended

•

continued substance use despite adverse
recurrent social/interpersonal problems

•

repeat inability to fulfill major
obligations at work, school, or home

•

repeatedly putting oneself or others in
physically harmful situations.

•

• desire or unsuccessful efforts to cut
persistent
down or control substance use

•

repeated substance-related legal
problems.

•

excessive
• amounts of time spent in obtaining
and using the substance or recovering from
its effects
• substance use despite adverse
continued
recurrent social/interpersonal problems

•

•

•

•
•

• of persistent physical or
awareness
psychological problems likely caused by
substance use without deterring its use
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Table 2
Criteria for Alcohol Use Disorder Used in the 2015 Through 2017 NSDUH Based on DSM-IV Criteria

•

spent a lot of time engaging in activities related to alcohol use

•

used alcohol in greater quantities or for a longer time than intended

•

developed tolerance

•

made unsuccessful attempts to cut down on use

•

continued use despite physical health or emotional problems associated with alcohol use

•

reduced or eliminated participation in other activities because of alcohol use

•

experienced withdrawal symptoms when cutting back or stopping use

Among the 5.3 million young adults who needed substance use treatment in 2016,
approximately 2.5 million were treatment-eligible for an illicit drug use problem, with
3.8 million treatment eligible for an alcohol use problem (Park-Lee, et al., 2017). Results from
2016 NSDUH, estimated that only 383,000 (7.2%) of these young adults, received SUD
treatment at specialty substance use treatment facilities compared to 1,756 (12.1%) older adults
(Park-Lee, et al., 2017). A specialty treatment facility was defined by NSDUH as treatment
received at drug or alcohol rehabilitation facilities (inpatient or outpatient), hospitals (inpatient
services only), and mental health centers (Bose, et al., 2017). Compared to older adults with
SUD, a larger proportion of younger adults with SUDs needed treatment; however, a much
smaller proportion received treatment. Therefore, given the notable disparity between younger
and older adults regarding treatment needs for SUD compared to treatment receipt for SUD and
considering that persons with OUDs are a subset of those with SUDs, it was reasonable to
suspect that these disparities were similar among young adults with OUDs. Limitations in the
Park-Lee and colleagues’ (2017) reporting on treatment needs and treatment receipts was the
exclusion of statistical significance levels and mean of estimates, in addition to exclusion of
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specific treatment types utilized. Bose and colleagues (2018) reported similar disparities
between young adults and older adults related to SUD treatment needs and the receipt of
substance use treatment.
Among the various SUDs, OUD accounted for the highest SUD mortality rate
(Bose, et al., 2017; Lipari, et al., 2016). Opioids encompassed a class of drugs that included the
illicit drug heroin and the licit prescription pain relievers oxycodone, hydrocodone, codeine,
morphine, fentanyl, and others (Kolodny, et al., 2015; NIDA, 2018a, 2018b). Opioids interact
with opioid receptors on nerve cells in the brain to produce feelings of euphoria and relieve pain,
and can be highly addictive.
Comorbidities and Concurrent Use of Substances
Two major concerns with the problem outlined earlier was the occurrence of
comorbidities and the concurrent use of substances. SUDs had been reported to occur in
conjunction with mental and/or medically related comorbidities (Ali, et al., 2015; Butler, et al.,
2017; Defoe, et al., 2019; Haughwout, et al., 2016; Jones, et al., 2017; Rodriguez-Sejias, et al.,
2017; Romo, et al., 2018; Wu, et al., 2016; Tragesser, et al., 2013). Mental comorbidities
included anxiety, mood, and behavioral disorders. Tragesser and colleagues, 2013 reported that
features of bipolar personality disorder (self-harm/impulsivity) were primarily associated with
opioid misuse. Common medical comorbidities which may occur with SUDs, included human
immunodeficiency virus infection, acquired immune deficiency syndrome, viral hepatitis
infections, and respiratory deficiencies (Kosten, & George, 2002; SAMHSA, 2015; CSUP,
2016).
Apart from mental and medically related comorbidities, concurrent substance use was
commonplace (Cohn, et al., 2018; Jones, et al., 2014; Wu, et al., 2011, 2016). Correlations had
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been found between the use of illicit substances and alcohol, among young adults and among
older adults (Cohn, et al., 2018; Jones, et al., 2019). In addition, multivariable models were
applied showing substance use problems associated with alcohol, cigarettes, and marijuana use.
The Focus on Opioid Use Disorders Among Young Adults
This study focused on treatment utilization among young adults with OUD in the U.S.
OUD was described as a life-threatening medical condition and a major public health problem in
the U.S. In 2017, an estimated 445,000 (1.3%) young adults compared to 1.6 million (0.7%)
older adults had an OUD (Table 3). This meant that young adults had the most prevalent OUD
treatment needs between these two groups (Bose, et al., 2018). In addition, as OUD is a subtype
of SUD, it should be noted that only 641,000 of 5.2 million (12.6%) of young adults who needed
SUD treatment received treatment (Bose, et al., 2018). It was therefore important to conduct this
study to identify population characteristics significantly associated with treatment utilization
among young adults with OUD in the U.S. Knowing the associated population characteristics,
may provide insight into those at highest risk for non-use of OUD treatment. Other concerns with
OUD related to (a) comorbidities associated with SUDs, (b) concurrent substance use, (c) OUD
having the highest mortality rate compared to other SUDs, and (d) not finding data specific to
treatments needs and treatment receipts among young adults provided.
Medications for Opioid Use Disorder
The gold standard treatment for combating OUD was pharmacotherapy, in conjunction
with counseling and/or behavioral therapies (Abraham, et al., 2017; FDA, 2018; Sofuoglu,
et al., 2018). There was no consensus on the ideal length of time for pharmacotherapy, however,
better health outcomes had been reported, when pharmacotherapy was used for longer periods.
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Table 3
Substance Use Disorders in 2017 Among the U.S. Population by Age Group: (thousands and percent)
Substance use disorders

Young adults

Older adults

Alcohol use disorder

3.4 million (10.0 %)

10.6 million (5.0%)

Marijuana use disorder

1.8 million (5.2%)

1.7 million (0.8%)

Prescription pain relievers

445,000 (1.3%)

1.6 million (.7%)

Prescription pain reliever use disorder

339,000 (1.0%)

1.2 million (0.6%)

Tranquilizer use disorder

278,000 (0.8%)

380,000 (0.2%)

Cocaine use disorder

243,000 (0.7%)

703,000 (0.3%)

Methamphetamine use disorder

188,000 (0.5%)

751,000 (00.4%)

Stimulant use disorder

187,000 (0.5%)

323,000 (0.2%)

Heroin use disorder

165,000 (0.5%)

483,000 (0.2%)

Bose, et al., 2018 study “Key Substance Use and Mental Health Indicators in the United States: Results
from the 2017 National Survey on Drug Use and Health”. https://www.samhsa.gov/data/sites/default/
files/cbhsq-reports/NSDUHFFR2017/NSDUHFFR2017.pdf

SAMHSA and NIDA recommended continuous treatment with MOUDs to ensure
effective treatment (SAMHSA, 2019d). Counseling and behavioral therapies aided in adherence
to MOUDs, which in turn, prevented relapse. MOUDs had not always been accessible to the
population that misused substances (Belenko, et al., 2013; Hadland, et al., 2018). In the U.S.
criminal justice system for example, most individuals entering the system was reported to be
misusing substances at the time of arrest (Belenko, et al., 2013; Bureau of Justice Statistics,
2020; National Institute of Correction 2017, n.d.). The criminal justice system had various
substance abuse treatment programs (alternative-to-prison, community-based supervision,
community-based treatment, prison-based treatment). MOUDs, however, was in limited use in
the criminal justice system due to the reported stigma associated with opioid substitution therapy,
the availability of resources to provide pharmacotherapy (financial, staffing), and possible risk of
diversion of treatment medications for illicit use.
6
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MOUDs Clarified. The U.S. Food and Drug Administration (FDA) approved the
following MOUDs: buprenorphine (BUP), methadone (METH), and naltrexone (NALT)
(SAMHSA, 2019b). METH is a full mu-opioid opioid (μOR) agonist and works by binding to
and activating all opioid receptors. NALT, a μOR antagonist, binds to and blocks all opioid
receptor sites. BUP is classified as a partial μOR agonist and works by binding to μORs while
reducing the overstimulation of the receptors (Chan, et al., 2020; Chen, et al., 2013; FDA, 2018;
D’Onofrio, et al., 2017; Greenwald, et al., 2014; Jones, et al., 2015a; Jones, et al., 2015b;
Mattick, et al., 2014; Medscape, 2020; NIDA, 2017b; SAMHSA, 2019a, 2019c; Smith, 2014;
Stone, et al., 2018; White, et al., 2014). A comparison of the three FDA-approved MOUDs is
shown in Table 4.
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Table 4
A Comparison of Medications for Opioid Use Disorder: Buprenorphine, Methadone, Naltrexone
Buprenorphine (BUP)

Methadone (METH)

Naltrexone (NALT)

a partial mu-opioid receptor (μOR) agonist
for treating OUD

a full μOR agonist for treating OUD

it binds to and reduces. the overstimulation of
the receptors

it binds to and activates all receptors.

reduces opioid withdrawal symptoms and use
of illicit opioid use

reduces opioid withdrawal symptoms and
use of illicit opioid use

reduces drug craving

reduces drug craving

reduces drug craving

Prescribing/
Administering

can be prescribed by a qualified physician,
physician assistant or nurse practitioner in a
certified opioid treatment program (OTP) or
office-based practice

must be administered each day at a
specially licensed clinic

can be prescribed by a qualified
physician, physician assistant or
nurse practitioner in a certified OTP
or office-based practice

Formulation

it is available as a sublingual film, extendedrelease injectable, subdermal implant

it is available as a tablet, or oral solution

it is available as an extended-release
injection or in daily oral formulation

special training/waiver requirement needed to
prescribe BUP

no special training or waiver requirement
to prescribe METH

no special training or waiver
requirement to prescribe NALT

Average dosage

average dose ranges from 1-2 mg to
16-32 mg

the average dosage is 40mg; dosing starts
at 10 to 20 mg and increase in 10mg
increments until the withdrawal symptoms
are controlled

the dosage is 50mg, 25mg over two
days orally/day, or 0.2mg
increments up to 0.8mg injectable

Diversion of drug

potential for diversion to non-medical use

potential for diversion to non-medical use

̶

Ceiling effect of drug

it has a ceiling effect (lowers the risk of
misuse, and side effects on respiration)

it has no ceiling effect (unless individual is
dependent on high doses of opioids and
can be fatal due to respiration depression)

retention rates at approximately 93% were
reported for extended-release (XR) 6-month
BUP implants and for daily formulations in
an outpatient specialty treatment center

an 89% retention rate was reported in a
single methadone treatment program
between, November 1st, 2016, and August
31st, 2017, in Rhode Island

Action

Outcome of use

8

Six-month retention
rate

it is a μOR antagonist.
it works by binding to and blocking
receptor sites; also used for AUD
treatment.
reduces illicit opioid use

̶

retention rates at approximately
53% were reported for the XR
formulation in an inpatient/
outpatient specialty treatment center
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Prescribing and administering standards for MOUDs had impeded its access (Anderson
& Kearney, 2000; Chen, et al., 2013; FDA, 2018; Greenwald, et al., 2014; Jones, et al., 2015a;
Jones, et al., 2015b; Mattick, et al., 2014; McNicholas, 2004; Medscape, 2020; NIDA, 2017b;
SAMHSA, 2019a, 2019c, 2019d; Smith, 2014; White, et al., 2014). To prescribe BUP for longterm opioid treatment, physicians in opioid treatment clinics and office-based facilities needed
special waivers (SAMHSA, 2019c; The President’s Commission, 2017; Thomas, et al., 2014).
In addition, physician assistants and nurse practitioners had only recently been added as
prescribers of BUP and NALT in certified opioid treatment programs (OTPs) or office-based
practices with MOUDs. Certified OTPs conformed to the Code of Federal Regulations, CFR 42Part 8, governing treatment with MOUD (OFR, 2016). The required daily visit to specially
licensed clinics for METH administration also hindered its access. Another medication,
naloxone (NAL), μOR antagonist, was FDA approved for treating opioid overdose (SAMHSA,
2020a). A combination medication formulated with BUP and NAL was used to decrease the
potential of BUP being diverted and misused.
MOUDs had been found to decrease premature morbidity among individuals with OUD
(Fiellin, et al., 2014; Weiss & Rao, 2017). Similar positive outcomes had been demonstrated
specifically with a combination of BUP/NAL. BUP/NAL maintenance therapy was investigated
in a Prescription Opioid Addiction Treatment Study (POATS; Weiss & Rao, 2017). This study
was the first large-scale study, conducted by the National Drug Abuse Treatment Clinical Trials
Network, with a sample of patients who were dependent on prescription opioids. The outcome
of the study supported the use of BUP/NAL for treatment of prescription opioids dependence.
Similar success for the use of MOUDs was reported by other investigators (Committee on
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Substance Use and Prevention, [CSUP], 2016; Fiellin, et al., 2014; Gibson, et al., 2008; Mattick,
et al., 2009; Mattick, et al., 2014; Sofuoglu, 2018; Thomas, et al., 2014).
Encouraging Usage of MOUDs. The utilization of MOUDs had been encouraged with
the passing of legislation in some states (Centers for Disease Control and Prevention [CDC],
2018b; Davis, et al., 2013). The Vermont 303 Bill, in conjunction with Section 2703 of the
Patient Protection and Affordable Care Act (ACA) resulted in a statewide hub-and-spoke
structured system for OUD treatment (Brooklyn & Sigmon, 2017). Hubs (typically an OTP)
were locations where BUP-waivered providers inducted patients with OUD into MOUDs.
Spokes were step-down clinics where patients were placed after stabilization and for continued
treatment (ASPE/HHS, 2020; National Academies of Sciences, Engineering, and Medicine
[NASEM], 2018). Colorado and Maryland had laws (SB19-008, HB116) which require county
jails to phase in MOUD treatment programs. Louisiana and Utah had revised their laws to
expand the number of practitioners who provided MOUDs. SAMHSA had certified OTPs to
utilize pharmacotherapy for people diagnosed with OUD. To further encourage usage of
MOUD, most states had office based BUP treatment facilities which serve to increase access to
MOUD (NSDUH, 2017a; SAMHSA, 2018c).
Barriers to Treatment
Despite actions taken to encourage usage of MOUDs, barriers existed that hindered
access to these medications (Abraham, et al., 2017; Alderks, 2017; KFF, 2019; The President’s
Commission on Combating Drug Addiction and the Opioid Crisis [The President’s Commission,
2017]). Barriers had resulted in a lower prevalence of MOUDs in rural (vs metropolitan) areas
(The President’s Commission, 2017). In 2016, 55% of rural counties did not have a SUD
treatment facility compared to national figures which showed 38% of all U.S. counties (N =
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3,141) did not have a SUD treatment facility. Furthermore, 85% of all U.S. counties did not
have an OTP that provided MOUDs.
Apart from the scarcity of MOUD facilities in rural areas, the availability of qualified
physicians with Drug Enforcement Administration (DEA) waivers to administer BUP had been a
hinderance to treatment utilization in rural areas (MACPAC, 2018; The President’s Commission,
2017). Waivered qualified physicians prescribed BUP from office-based practices, or at
substance abuse treatment facilities. However, the number of patients to which a waivered
physician could prescribe BUP, was limited to 100, with further expansion to 275 patients after a
year (Alderks, 2017; Holly, et al., 2018; The President’s Commission, 2017; SAMHSA, 2020b).
In 2016, 47% of U.S. counties did not have a DEA-waivered physician (The President’s
Commission, 2017), with more than half of the physicians in rural areas having a 30-patient
waiver and not treating any patients. Other healthcare providers (nurse practitioners, clinical
nurse specialist, certified registered nurse anesthetists, certified nurse midwives) had been added
to the list of eligible BUP providers in the office setting, but only until 2023 (SAMHSA, 2020b).
Barriers had also been created by Centers for Medicare and Medicaid Services (CMS)
coverage policies concerning SUDs (Barry, 2010; MACPAC, 2018; The President’s
Commission, 2017). One specific example related to barriers created by the CMS Institution of
Mental Diseases (IMD) exclusion, in effect since the inception of Medicaid in 1965. The IMD
exception prohibited payment to IMD facilities for diagnosing, treating, or caring for persons
with mental diseases, which included substance use disorders (SUDs). Despite this setback,
most states Medicaid programs offered SUD services, however, coverage gaps (residential
treatment) existed. Some states were also not applying for Medicaid Section 1115 demonstration
waivers, introduced to pay for short-term stay of adults in IMD settings (MACPAC, nd). As of
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April 2018, only 12 states had participated to pay for full clinical SUD treatment services (CMS,
nd; MACPAC, 2018). These services included MOUDs, outpatient and residential treatment for
SUD.
The 2010 ACA interceded to change these conditions by providing greater access to
substance use treatment through coverage expansions and establishment of requirements for
coverage of SUD treatments in private and public insurance plans (ACA, 2010). Other barriers
were unaffordable copayments and limitations in annual SUD treatment visits stipulated in
coverage policies.
The Response to Opioid Use Disorder
The ACA expanded Medicaid, creating stipulations that were beneficial for substance use
treatment (the mandate for coverage under parental insurance and coverage for preexisting
conditions like prior SUD treatment; Abraham, et al., 2017; ACA, 2010). A notable downside of
the ACA, however, was that there were no stipulations on the type of SUD treatment services
which should be provided (Abraham, et al., 2017). As such, states had the leeway in the range of
SUD treatment services offered to individuals with OUD and in determining whether to adopt
Medicaid expansion (Abraham, et al., 2017). Fourteen states had not adopted Medicaid
expansion (KFF, 2019). A leading national society on addiction medicine, the American Society
of Addiction Medicine (ASAM) outlined guidelines and called for insurance companies to
provide a range of treatment services (MOUDs, residential and outpatient treatment,
detoxiﬁcation, recovery and support services) to meet the needs of individuals with OUD
(ASAM, 2016; MACPAC, 2018).
Other federal guidelines were in place to support MOUD usage and to lessen substance
use treatment barriers. The Substance Use Disorder Prevention that Promotes Opioid Recovery
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and Treatment for Patients and Communities (SUPPORT) Act of 2018, increased the availability
of MOUD providers, by allowing varied healthcare providers to prescribe BUP in office-based
settings (SAMHSA, 2020b). The Act also created a new state plan option to allow states to pay
for care for Medicaid beneficiaries with at least one SUD in certain IMDs (MACPAC, 2018).
In addition, the 2015 Federal Guidelines for Opioid Treatment Programs supported
accrediting organizations in the development of accreditation standards. These guidelines
provide OTPs with information on how programs can achieve and maintain compliance with
federal regulations by delivering patient-centered care that was integrated and focused on
recovery-oriented standards for substance use treatment. The Comprehensive Addiction and
Recovery Act (CARA) of 2016 provided for the awarding of grants to address the prescription
opioid abuse, the heroin use crisis, and for other purposes (preventing addiction related to youth
sports injuries, improving access to overdose treatment, National Institute of Health (NIH) opioid
research, first responder training, prescription drug take back expansion, MOUD for recovery
from addiction; Congress.gov [2016]).
It was evident that the OUD responses were inefficient in providing adequate opioid
treatment facilities, sufficient qualified healthcare providers to administer MOUDs in rural areas,
limited annual OUD treatment visits stipulated in insurance plans, and appropriate CMS
coverage policies and payment options for OUD treatment. Other barriers which affected
treatment utilization may have existed. These undetermined barriers for young adults with OUD
in the U.S. may be found by applying the propositions of ABM.
Prior studies examined treatment utilization for SUD in the various contexts. In a
statewide study, Liebling and colleagues (2016), compared young adults (18-29 years) who had
enrolled in substance use treatment without facing barriers, young adults who attempted to enroll
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but faced barriers and young adults who attempted to enroll but were unsuccessful. Barriers
were also examined among Latino persons with SUDs (Pinedo, et al., 2018). The trends in
treatment utilization, correlates of treatment utilization, and treatment types and settings among
adolescent with and without SUD were examined by Haughwout and colleagues (2016). Studies
also addressed treatment for SUDs, mental health comorbidities, perceived need, and barriers to
care (Novak, et al., 2019; Rodriguez-Sejias, 2017). The involvement of the criminal justice
system in relation to treatment use for co-occurring disorders (mental health and/or SUD) was
reported by Belenko and colleagues (2013) and Nam and colleagues (2016). In cross-sectional
studies, correlates of treatment among various population groups with OUD were examined
(Romo, et al., 2018; Wu, et al., 2011, 2017). Insurance coverage status, post ACA, as a correlate
of treatment utilization was also addressed (Saloner, et al., 2017; Young-Wolff, et al., 2017).
Correlates like, concurrent substance use, sexual orientation, and insurance were the focus in
other studies (Ali, et al., 2015, 2017; McCabe, et al., 2013; Saloner, et al., 2017). Hadland and
colleagues (2018), in a case series examined stigma as a barrier to SUD treatment among young
adults.
A gap existed in literature that focused on treatment utilization as it applied to young
adults with OUD in the U.S. The association of multi-dimensional population characteristics
(demographics, social, personal/family resources, and community resources) with treatment
utilization among young adults with OUD in the U.S. was not found.
Study Purpose
The primary purpose of this study was to address this gap in literature which focused on
treatment utilization among young adults with OUD in the U.S. The association of multidimensional population characteristics with treatment utilization among young adults with OUD
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in the U.S. was not found. The study was timely for various reasons, among which were, the
urgency posed by the high prevalence of opioid misuse among the young adult population, the
high opioid-related mortality rates, and the disparity between treatment needs and treatment
utilization for OUD among young adults in the U.S. (Bose, et al.,2017; Lipari, et al., 2016).
Further, the results of this study may provide valuable knowledge related to the
development of effective strategies to improve access to treatment and recovery support services.
The results may also enhance treatment engagement and utilization in young adults with OUD in
the U.S. Future studies that investigate treatment utilization for SUDs (including OUDs) may
also benefit from this study’s findings.
This study sought to associate a broad array of population characteristics with treatment
utilization among young adults with OUD in the U.S. Characteristics found to be significant in
the data analysis may be modifiable. Similarly, the identification of significant characteristics
that were non-modifiable was important. Modifiable and non-modifiable characteristics may
provide important evidence in the development or enhancement of strategies to encourage
treatment utilization among young adults with OUD in the U.S. In the absence of such scientific
evidence, it may be challenging to develop new treatment strategies or enhance existing ones,
thereby allowing the opioid health crisis to persist. Consequently, young adults in the U.S. may
likely continue to be affected by OUD. The long-term goal of this research was to add to a
scientific knowledge base to inform actions to address OUD among young adults in the U.S.
Theoretical Framework
The expanded version of the ABM (Figure 1) incorporated characteristics relevant to a
traditional and/or a vulnerable population and was used to guide the study. The ABM defined
vulnerable populations as those who were at greater risk for poor health, experience disparities in
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life expectancy and morbidity or had limited access to and use of healthcare services
(Gelberg, et al., 2000). The vulnerable population was also described as consisting of
individuals who used drugs.
The ABM proposed various population characteristics in the traditional and vulnerable
domains which may be associated with treatment utilization. The model suggested that treatment
utilization was a function of a predisposition by people to use treatment services, factors that
enable or impede such use, and people's need for care (Gelberg, et al., 2000). The population
characteristics were therefore categorized as predisposing, enabling or needs based (Aday &
Andersen, 1974; Andersen, 1968, 2008; Gelberg, et al., 2000). Further, the ABM recognized
that individuals in the traditional/vulnerable domains had their own personal practices like selfcare, exercise, and diet. Health services were posited to be used in the traditional domain, but
not in the vulnerable domain. Further, the maintenance and improvement of individuals’ health
status (based on their own perceptions or an evaluated health status), including satisfaction with
care, were the explicit outcomes. Outcomes would then influence subsequent predisposition,
enabling resources, need, and health behaviors.
Considering the propositions of the framework, the proposal was that treatment
utilization among young adults with OUD was associated with the ABM’s predisposing,
enabling, and needs characteristics in the traditional and/or vulnerable domains. To develop
scientific knowledge of treatment utilization among young adults with OUD in the U.S., a
secondary analysis of a subset of the ABM characteristics which be associated with ABM
characteristics was performed.
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FIGURE 1
The Population Characteristics of Andersen Behavioral Model for Traditional/Vulnerable Populations Examined in This Study
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Research Question and Hypotheses
The literature suggested that treatment utilization for OUD and other SUDs among
adolescents and adults older greater than 25 years was associated with various social and
personal/family characteristics (education, income, employment status, insurance coverage,
comorbidities, co-occurring disorders, presence of mental health illness, perceived need, sexual
orientation, arrest history, abuse of other substances), community resources or perceived health.
These characteristics were considered as predisposing, enabling or need characteristics in the
ABM (Ali, et al., 2015, 2017; Belenko, et al., 2013; Gelberg, et al.,2000; Hadland, et al., 2018;
Haughwout, et al., 2016; Liebling, et al., 2016; McCabe, et al., 2013; Nam, et al., 2016; Novak,
et al., 2019; Pinedo, et al., 2018; Rodriuez-Sejias, 2017; Romo, et al., 2018; Saloner, et al., 2017;
Wu, 2011; Wu, et al., 2016; Young-Wolff, et al., 2017). Covariates examined in prior treatment
utilization studies demonstrated the association of treatment utilization with a subset of the ABM
characteristics among adolescent or among adults. The outcomes of these prior treatment
utilization studies were not generalizable to the young adult population with similar or additional
population characteristics. Further, treatment utilization among young adults with OUD was
understudied. Therefore, the research question for this study was: What are the predisposing,
enabling, and needs characteristics as posited in the Andersen Behavioral Model that are
significantly associated with treatment utilization among young adults with opioid use disorder
in the United States?
Hypotheses
Hypothesis One. One or more prior studies found that the individual more likely to
utilize OUD treatment was an adult, non-Hispanic white female, with less than a high school
education and not in the labor force (Hadland, et al., 2018; Haughwout, et al., 2016; Liebling,
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et al., 2016; Pinedo, et al., 2018; Romo, et al., 2018; Wu, et al., 2011, 2016). Not in the labor
force was interpreted as being disabled, keeping house full-time, in school/training, retired, or
not having a job for some other reason. The likelihood of treatment utilization was also reported
as positively associated to parent communication, household size, arrest history, and nonheterosexual. The consensus in reports was that in the presence of co-morbidities or cooccurring SUDs, treatment utilization for OUD increased. A longitudinal study which explored
treatment utilization for SUD among homeless youth (12-24 years), utilizing SAMHSA national
treatment data for the years 1992-2017, found that homeless youths had higher odds to self-refer
to treatment compared to housed youths (Green, et al., 2020). Determining whether perceived
need translated into higher treatment for OUD showed mixed results (Haughwout, et al., 2016;
Romo, et al., 2018; Wu, et. al., 2011). In Romo and colleagues’ (2018) study, more recent data
(2010-2014) was used for analysis and included individuals ≥ 18 years (within which the young
adult falls). Their findings on perceived need supported the argument that a lack of perceived
need of treatment resulted in reduced treatment utilization.
Therefore, it was hypothesized that among young adults with OUD in the U.S., the
predisposing characteristics (older age, female gender [gender was described as male or female
by the NSDUH], never married, non-veteran/military status, perceive need of treatment, nonHispanic White race/ethnicity, having less than a high school education, not part of the labor
force, parent communication, household size, non-heterosexual, homelessness, arrest history,
presence of mental illness, existing comorbidities, co-occurring SUDs) are positively associated
with treatment utilization.
Hypothesis Two. It was difficult to determine based on evidence whether having
insurance translated into higher treatment for OUD. Haughwout and colleagues (2016),
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Liebling and colleagues (2016), Romo and colleagues (2018) found a negative association with
insurance coverage and SUD treatment among adolescents and adults. Wu and colleagues
(2016) found an inverse association. Intuitively, one may assume that having insurance should
provide more access to SUD treatment resulting in a positive association with treatment
utilization and insurance. A positive association with SUD treatment utilization was evidenced
among adults having a high income, (Haughwout, et al., 2016; Romo, et al., 2018; Wu, et al.,
2011; Wu, et al., 2016). Adults receiving public assistance (defined as a program other than
Medicaid that pays for the last treatment one received, even if it paid only part of the cost) had a
positive likelihood of obtaining substance use treatment for OUD. Living in a large
metropolitan area also increased treatment utilization, as confirmed by Wu and colleagues
(2011, 2016) and by Romo and colleagues (2018).
Therefore, it was hypothesized that among young adults with OUD in the U.S., the
enabling characteristics high income, having insurance coverage, residing in a large
metropolitan area, and being on one or more public assistance program(s) are positively
associated with treatment utilization.
Hypothesis Three. Study findings by Romo and colleagues (2018) found that among
adults ≥ 18 years, good health condition had a positive association with treatment utilization.
Intuitively, one may assume that unless one’s health condition was poor, this finding may be
reproduced.
Therefore, it was hypothesized that among young adults with OUD in the U.S., the needs
characteristic, self-reported health condition was positively associated with treatment utilization.
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Hypothesis Four.
Studies that examined treatment utilization found a negative association with mental
illness and stigma (Ali, 2015, 2017; Hadland, et al., 2018; Novak, et al., 2019;
Rodriguez-Sejias, et al., 2017; Romo, et al., 2018; Wu, et al., 2011). These studies utilized
samples comprised of adolescents or adults.
As young adults are a subset of the adult population, it was hypothesized that among
young adults with OUD in the U.S., the predisposing characteristics mental illness and the
enabling characteristic, stigma are negatively associated with treatment utilization.
The variables in these hypotheses were established by the propositions in the ABM. A
subset of the proposed population characteristics in the ABM were selected to serve as
covariates. These covariates posited to associate with treatment utilization were categorized as
demographics, health beliefs, social structure, sexual orientation, childhood characteristics,
enabling characteristics (personal/family resources, community resources), and needs
characteristics (perceived health). The outcome variable for this study was treatment utilization,
which was based on the receipt of treatment in the past year.
Summary
The increasing SUD-related mortality rates, particularly due to OUDs and the disparity
between treatment need and treatment receipt for SUDs was alarming. Young adults had higher
SUD treatment needs. OUD, a subset of SUDs, heroin use disorder may lead to serious health
complications and even death. MOUDs were available and their use were encouraged, however
existing barriers discouraged or precluded treatment altogether. Treatment for OUD had been
reported to reduce mortality. Young adults with OUD need treatment. This study associated
demographics, social and personal/family characteristics posited in the ABM, with treatment
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utilization among young adults with OUD in the U.S. The study was important, timely and
necessary to advance scientific knowledge necessary to guide the development of effective
strategies and to enhance existing strategies to improve treatment engagement and treatment
utilization among young adults with OUD in the U.S.
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Chapter 2: Literature Review
To inform this secondary analysis, a literature search was performed to identify studies
that focused on treatment utilization among young adults with opioid use disorder (OUD) in the
U.S. A database search was conducted of peer-reviewed journals published from 2010 to 2018.
The year 2010 was selected for multiple reasons. First, notable events beginning in the 1990s
were the liberation of laws leading to the deregulation of opioid prescribing for pain management
(Kolodny, et al., 2015), increase in physician opioid prescribing, quadrupling of prescription
opioid sales in the years 2000 to 2010 and increased opioid overdose deaths (Sullivan & Howe,
2013). By 2017, 191 million opioid prescriptions were dispensed (CDC, 2017b; CDC, 2018a),
representing a triple increase compared to 1999 (CDC, 2018b). Non-medical opioid usage,
unintentional overdose deaths, prescription drugs misuse and dependence disorders saw a
significant increase (CDC, 2011; Compton & Volkow 2006; Daniulaityte, et. al., 2014; Gilson,
et al., 2001; Paulozzi & Annest, 2007; Paulozzi, et al., 2006; Paulozzi & Xi, 2008; SAMHSA,
2010b; Zacny, et al., 2003). Barriers (lack of health coverage, high cost of treatment and
unemployment) existed for individuals needing substance use treatment (CBHSQ, 2014). The
2010 ACA introduced reforms to the health care system, which were supposed to alleviate these
barriers and make health insurance coverage more affordable, improve access to health care
services for SUDs, and eliminate the loss of health insurance due to loss of employment
(CBHSQ, 2014). Disparities in treatment use and treatment needs for SUDs, including OUD,
were still reported in studies for the years 2015 and 2016 (Park-Lee, et al., 2016; 2017).
Second, a rising prevalence of prescription pain reliever and other opioid misuse and
dependence disorders were observed in 2010 (CDC, 2011; SAMHSA, 2010b). Third, the ACA
allowed states participating in ACA Medicaid expansion to offer SUD services (ACA, 2010).
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Fourth, in 2010, the rate of illicit drug use, including prescription opioids misuse was higher for
young adults (21.2%) up from 19.6% in 2008 than for adolescents (10.1%) up from 9.3% in 2008
and individuals over 25 years old (6.3%) in 2008 (SAMHSA, 2011). Examining the broad array
of ABM characteristics that relate to this study’s phenomenon, using 2010 as starting point for
the literature search seemed appropriate.
Search Strategy
CINAHL Complete, MEDLINE, Academic Search Complete, Social Science Full Text
(H.W. Wilson), PsychINFO, Proquest Dissertations & Theses Global databases, and Google
Scholar were searched using the keywords “treatment” and “opioid or painkiller” and “abuse or
misuse”. These terms were derived from the definition of the term OUD (SAMHSA, 2018b).
Keywords were further modified to include “treatment or intervention or therapy”, “opioids or
painkillers”, “abuse or misuse” and “young adults”. Duplicates were removed from the resulting
search outcome, titles and abstracts were screened, and inclusion and exclusion criteria applied.
Excluded were articles in which treatment utilization for OUD was not addressed or the focus
was on substances with the exclusion of opioids. Empirical studies show that treatment
utilization for OUDs was influenced by co-morbidities and other co-occurring SUDs. A second
search was conducted using the initial set of databases to include the search terms
“co-morbidities” and “co-occurring substance use disorders”. Duplicates were removed,
title/abstract screening performed, and exclusion criteria applied. Additional manuscripts that
focused on co-morbidities, co-occurring SUDs and treatment utilization were retrieved.
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Summary of the Literature
Treatment Utilization (Outcome Variable)
Treatment utilization among adolescents, young adults, and older adults with OUD, in the
presence of other SUDs, mental illness, and co-morbidities was examined in multiple studies
(Table 5). Studies that addressed characteristics defined in the ABM as scant. Survey estimates
indicated a high prevalence of SUDs in the U.S. (Bose, et al., 2017; Park-Lee, et l., 2017). The
rate at which individuals utilize SUD treatment, however, was shown to be consistently low
(Lipari, et al., 2016; Park-Lee, et al., 2017; Bose, et al., 2018).
Predisposing Characteristics Associated with Treatment Utilization
Demographics
Consistently low SUD treatment utilization had been reported in studies that provided
descriptive statistics on demographic characteristics (age, gender, and race/ethnicity).
Older Age. Adults > 25 years old used OUD treatment more frequently than young
adults, young adults used OUD treatment more frequently than adolescents. These findings were
reported in studies that investigated correlates to treatment utilization for OUD among
adolescents, adults and treatment use in the presence of mental illness and SUD among adults
(Romo, et al., 2018; Saloner & Karthikeyan, 2015; Wu, et al., 2011, 2016).
Gender. More females than males accessed OUD treatment among individuals
≥ 12 years old, while males with an arrest history tended to have increased SUD treatment
(Wu, et al., 2011; 2016; Hadland, et al., 2018; Haughwout, et al., 2016). These findings were
based on the survey of adolescents in a study by Haugwout and colleagues (2016) and Wu and
colleagues (2011, 2016) which focused on the past year’s substance use and trends in treatment
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utilization and in a study by Hadland and colleagues (2018) identifying time trends and
disparities in receipt of BUP and NALT among youths with OUD in the U.S.
Race/ethnicity. More White than non-White persons used OUD treatment, whereas
more Hispanic/Latino persons used OUD treatment more than Black persons (Hadland, et al.,
2018; Haughwout, et al., 2016; Liebling, et al., 2016; Pinedo, et al., 2018; Romo, et al., 2018).
Multiple studies investigated racial/ethnic disparities in the receipt of pharmacotherapy for OUD,
(Hadland, 2018, Haugwout, et al., 2016, Liebling, et al., 2016, Romo, et al., 2018). Pinedo and
colleagues (2018) investigated specialty treatment for SUD among a sample of White, Black,
and Latino participants with recent SUD. Latino persons were the only group to be discouraged
from using services not culturally appropriate (family over individual, respect based on age and
social position, acknowledgment of social contexts).
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Table 5
Characteristics Associated with Treatment Utilization for SUD Among Adolescents (12 – 17 years), Young Adults (18- 25 years) and Older Adults Over 25 Years Old
Characteristics
examined
Age

Adolescents

Being an adolescent
with an OUD had a
negative relationship
with utilizing OUD
treatment (Wu, et al.,
2011)

Young adults

≥ 12 years old
̶

Young adults used opioid
treatment more than
adolescents (Wu, et al., 2016)

̶

More females than males
used opioid specific treatment
(Wu, et al., 2016)

Marital status

̶

̶
̶

Veteran/military
status

̶

̶

̶
̶

̶
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Perceived need

Perceived need
increased SUD
treatment use among
adolescents
(Haughwout, et al.,
2016)

Most adults did not use treatment
for OUD (Romo, et al.,2018;
Saloner & Karthikeyan, 2015)

Older adults over 25
years old
This group used opioid
treatment more than young
adults (Romo, et al.,2018)
Adults in this group used
opioid treatment more than
adolescents (Wu, et al., 2016)

More males than
females used SUD
treatment, including for
OUD (Hadland, et al.,
2018; Haughwout,
et al., 2016; Wu,
et al., 2011)

Gender

≥ 18 years old

̶

Younger men used less tobacco
treatment (Young-Wolff, 2017)

Adults with OUD and were never
married had a higher usage of
specialty treatment use as
compared to those who were
separated/widowed/separated or
married (Romo, et al., 2018)
̶
Results indicated that increased
service utilization was associated
with perceiving a need for
substance abuse treatment (Ali,
Teich, & Mutter, 2015).
When they received treatment,
they were more likely to receive
mental health treatment (Ali,
Teich, & Mutter, 2015).
Lack of a perceived need for OUD
treatment decreased treatment use
(Romo, et al., 2018)

̶

̶
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Table 5
Characteristics Associated with Treatment Utilization for SUD Among Adolescents (12 – 17 years), Young Adults (18- 25 years) and Older Adults Over 25 Years Old
Characteristics
examined
Race/
ethnicity

Adolescents
Treatment use had a
negative relationship
among non-Hispanic
Black persons, Hispanic
males, non-Hispanic
female who had a SUD
compared to White
persons (Haughwout,
et al., 2016)

Young adults
Non-White persons had a
lesser chance of treatment use
for OUD (Liebling, et al.,
2016)

≥ 12 years old
Blacks and Native
Hawaiian/Pacific Islander,
and Asian American persons
particularly underutilized
opioid-specific treatment
much less compared to White
persons (Wu, et al., 2016)

≥ 18 years old
Hispanic adults used OUD
specialty treatment more than
Black, and non-Hispanic White
adults (Romo, et al., 2018)

Latino persons more than Black
and White persons underutilized
specialty treatment for SUDs
(Pinedo, 2018)
Latino persons who perceived a
need for alcohol or drug
treatment were more likely to
use mental health treatment
versus substance abuse
treatment (Pinedo, 2018)

Hispanic, mixed race, and
Native American persons
used opioid specific treatment
less than White persons (Wu,
et al., 2016)

Black and Hispanic
persons used OUD
treatment less than
White persons
(Hadland, 2018; Wu,
et al., 2011)

Older adults over 25
years old

Asian and Latino smokers used
less tobacco treatment (YoungWolff, et al., 2017)

28

Education

̶
̶

̶

Adults with less than a high school
education used specialty treatment
more than college graduates
(Romo, et al., 2018)

Employment

̶
̶

̶

Not being in the labor force and
having OUD had a positive
association with specialty
substance use treatment as
compared to those employed
full/part-time or unemployed
(Romo, et al., 2018)

Parent
communication

Talking to parents
increased SUD
treatment use, including
OUD treatment use
(Haughwout, et al.,
2016; Wu, et al., 2011)

̶
̶

̶

̶

̶

̶
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Table 5
Characteristics Associated with Treatment Utilization for SUD Among Adolescents (12 – 17 years), Young Adults (18- 25 years) and Older Adults Over 25 Years Old
Characteristics
examined

Adolescents

Young adults

≥ 12 years old

≥ 18 years old

Older adults over 25
years old

Household with one individual,
sought specialty treatment for
OUD less than household in which
there were two, three, four or more
people (Romo, et al., 2018)

̶

̶

̶
̶

Sexual
orientation
̶

̶
̶

̶

Homelessness
̶

Young adults (18 - 29 years)
with OUD and were homeless
showed decreased treatment
use for OUD (Liebling, et al.,
2016)

̶

̶

Males with an arrest
history increased SUD
treatment (Haughwout,
et al., 2016)

Young adults (18 - 29 years)
with OUD and had an arrest
history showed decreased
treatment use for OUD
(Liebling, et al., 2016)

̶

Having an arrest history with OUD
had a positive association with
specialty substance use treatment
(Romo, et al., 2018)
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Household size

Arrest history

̶

̶

̶

̶

Adults with an arrest history were
more likely than those without an
arrest history to receive mental
health treatment or substance
abuse treatment alone. (Nam,
et al., 2016)

Adolescents with OUD
and an arrest history
had a positive
relationship with
treatment use (Wu,
et al., 2011)
Mental illness

Heterosexual men were more
likely to report substance abuse
treatment than were
heterosexual women (McCabe,
et al., 2013)

̶

Adults with serious mental illness
used specialty treatment for OUD
more than those with no mental
illness or mild mental illness or
moderate illness (Romo, et al.,
2018)

In the presence of comorbid
conditions (mental illness),
SUD had a negative relationship
with treatment use, but the
mental illness had a positive
relationship with treatment use
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Table 5
Characteristics Associated with Treatment Utilization for SUD Among Adolescents (12 – 17 years), Young Adults (18- 25 years) and Older Adults Over 25 Years Old
Characteristics
examined

Adolescents

Young adults

≥ 12 years old

≥ 18 years old

Older adults over 25
years old
(Ali, et al., 2015)
In the presence of comorbid
conditions (OUD and mental
illness), OUD had a negative
relationship with treatment use.
but the mental illness had a
positive relationship with
treatment use (Novak, et al.,
2019)
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In the presence of OUD and
serious mental illness,
treatment use increased for
both co-occurring conditions
as opposed to the co-occurring
conditions OUD and mild
mental illness (Novak, et al.,
2019)
̶

Other substance SUD treatment use had
use /
a positive relationship
comorbidities
in the presence of other
SUDs except alcohol
use disorder
(Haughwout, et al.,
2016).

People with alcohol use
disorder used treatment less
than people with OUD (Wu,
et al., 2016)

Higher income was
positively associated to
treatment use (Wu,
et al., 2016)

Treatment for mood/anxiety
disorder increased in the
presence of SUDs (RodriguezSejias, et al., 2017)

Low treatment use with
severe patterns of OUD and
SUD comorbidity (Wu, et al.,
2016)

In the presence of OUD
and SUD comorbidities,
treatment use increased
(Wu, et al., 2011)
Income

Having another SUD with OUD
had a positive association with
specialty substance use treatment
(Romo, et al., 2018)

̶

Those with higher income
used more opioid specific
treatment (Wu, et al., 2016)

̶

̶
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Table 5
Characteristics Associated with Treatment Utilization for SUD Among Adolescents (12 – 17 years), Young Adults (18- 25 years) and Older Adults Over 25 Years Old
Characteristics
examined
Insurance
coverage

Adolescents
SUD treatment use had
a negative relationship
with the individual’s
insurance coverage
status (Haughwout,
et al., 2016)
Adolescents with OUD
and covered by private
were less likely to use
OUD treatment (Wu,
et al., 2011)

Young adults
Insurance was not associated
with treatment use for OUD.
Study sample was small and
the state where study was
conducted was a Medicaid
expansion state. (Liebling,
et al., 2016)

≥ 12 years old

≥ 18 years old

Those with insurance used
opioid specific treatment
more than those with no
insurance (Wu, et al., 2016)

Lack of insurance decreased
treatment use for OUD (Romo,
et al., 2018)

People with public insurance
used OUD treatment more
than people with private
insurance (Wu, et al., 2016)

Adults with OUD and public
insurance used specialty
treatment more than people with
private insurance or no insurance
(Wu, et al., 2016)

Older adults over 25
years old
No significant difference
(McCabe, et al., 2013)
The decision to seek treatment
for substance abuse was
contingent on insurance and
having a perceived need. Those
who sought treatment from selfhelp groups were excluded (Ali,
et al., 2015)
Medicaid smokers were more
likely to use patient tobacco
treatment to exchange and
commercial (Young-Wolff,
et al., 2017)
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Individuals with mental and
SUDs, in the presence of
coverage had a negative
relationship with treatment use
(Saloner, et al., 2017)
Residence

Adolescents in small
metropolitan locations
used OUD treatment
less than people in large
metropolitan locations
(Wu, et al., 2011)

Stigma

Stigma among
adolescents with OUD
had a negative
relationship treatment
use (Wu, et al., 2011)

̶

Stigma had a negative
relationship with SUD
treatment (Hadland, et al.,
2018)

People in small metropolitan
locations used OUD
treatment less than people in
large metropolitan locations
(Wu, et al., 2016)

̶

Residence in a non-metropolitan
county was negatively associated
with receiving specialty substance
use treatment for OUD (Romo,
et al., 2018)
̶

̶

Stigma had a negative
relationship with SUD treatment
especially among those with
private insurance (Ali, et al.,
2017)
Stigma had a negative
relationship with opioid use
disorder treatment (Novak,
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Table 5
Characteristics Associated with Treatment Utilization for SUD Among Adolescents (12 – 17 years), Young Adults (18- 25 years) and Older Adults Over 25 Years Old
Characteristics
examined

Adolescents

Young adults

≥ 12 years old

≥ 18 years old

Older adults over 25
years old
et al., 2019)

Receipt of
public
assistance

Health condition

No difference in SUD
treatment among those
with public insurance or
no insurance
(Haughwout, et al.,
2016)

̶

̶

Adults with OUD and receiving
public assistance had a positive
relationship with using treatment
for OUD (Romo, et al., 2018)

̶

̶
̶

Individual with good health and
OUD, used OUD specialty
treatment more than those with
excellent/very good or poor/fair
health (Romo, et al., 2018)

Persons covered by Medicaid or
receiving other forms of public
assistance were more likely to
receive substance abuse
treatment than the privately
insured (Ali, 2015)
̶
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Perceived Need for Treatment
Ali and colleagues (2015) had found a high percentage (97%) of adults did not perceive a
need for treatment and 80% did not receive treatment in the analysis of five years (2008 - 2012)
of NSDUH data. The aim of the study was to understand the role health insurance played in
influencing the use of substance abuse treatment and/or mental health treatment, given there was
a perceived need for treatment. Results from their study indicated that increased treatment
utilization was associated with perceiving a need for substance abuse treatment. Similar results
were found in a nationally representative sample of adults with OUD, in a cross-sectional study
based on the years 2010 to 2014 (Romo, et al., 2018). Romo and colleagues examined correlates
of treatment utilization among adults. Haughwout and colleagues (2016) found a positive
relationship between perceived need and SUD treatment utilization among adolescents in a
pooling of NSDUH data for the years 2002 - 2013. In these studies, the response to the question:
“during the past 12 months, did you make an effort to get treatment or counseling” for drug use,
determined perceived need for treatment.
Education, Employment, Household Size, Arrest History, Homelessness, Concurrent
Substance Use, Comorbidities
Increases in SUD treatment among adults were associated with having less than a high
school education and not being in the labor force or unemployed (Haughwout, et al., 2016;
Romo, et al., 2018; Wu, et al., 2011; Wu, et al., 2016). Unemployed meant on layoff or looking
for work. Those who lived alone were reported to have decreased SUD treatment utilization.
Employed persons had treatment limitations in their employee-sponsored insurance plans, and
faced stigma, while the unemployed were covered by Medicaid and other state plans or were part
of the criminal justice system allowing for more access to SUD treatment (Ali, et. al., 2017;
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Belenko, et al., 2013; Bureau of Justice Statistics, 2020; Hadland, et al., 2018; IRS, 2020;
National Institute of Correction 2017, n.d.). OUD treatment among individuals ≥ 12 years old
had a positive relationship with arrest history (Haughwout, 2016; Liebling, et al., 2016; Romo,
et al., 2018; Wu, et al., 2011). Additionally, homelessness had a negative associated with SUD
treatment (Ali, et al., 2017; Hadland, et al., 2018; Liebling, 2016; Novak, et al., 2019). Low rate
of SUD treatment utilization was associated with concurrent use of substances (Wu, et al., 2016).
Rodriguez-Sejias and colleagues (2017) found a positive association with SUD treatment
utilization and comorbidities among a nationally representative sample of adults. Other studies
showed similar associations with comorbidities and OUD/SUD treatment utilization, among
adolescents and adults (Haughwout, 2016; Romo, et al., 2018).
Mental Illness
The ABM suggested that mental illness, a predisposing characteristic, played a role in
treatment utilization. The literature found, reported that adults with OUDs and co-occurring
mental illness, sought treatment for mental illness rather than for OUD (Ali, et al., 2015; Novak,
et al., 2019). Similarly, Rodriguez-Sejias and colleagues’ (2017) study based on a nationally
representative sample of adults, focused on individual mental disorders and found that treatment
utilization for SUD decreased, in the presence of mood and anxiety disorders.
Enabling Characteristics Associated with Treatment Utilization
Insurance
Insurance was an enabling characteristic posited in the ABM to associate with treatment
utilization. Among adolescents in the years 2002 - 2013, Haughwout and colleagues (2016)
reported a negative relationship between insurance coverage status and SUD treatment. The
same negative association was observed among a small sample of young adults (18 - 29 years) in
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a Medicaid expansion state (Liebling, et al., 2016) and among adults (in the years 2010 - 2014)
with OUD (Romo, et al., 2018). Wu and colleagues (2016), however, found an inverse
association, in the analysis of NSDUH data for the years 2005 - 2013. Individuals ≥ 12 years
with public insurance coverage used OUD treatment more than young adults with no insurance.
Individuals having public insurance were more likely to use OUD treatment than individuals
with private insurance (Ali, et al., 2017; Wu, et al., 2016). Further, Wu and colleagues (2016)
found that having Medicaid or private insurance was associated with a greater likelihood of
receiving SUD treatment, but only when the individual perceived a need for it, compared to
being uninsured and not perceiving a need for treatment. The multiple analysis of the potential
impact of insurance coverage on treatment utilization posed uncertainties in determining whether
having insurance coverage translated into an increased or decreased rate of SUD treatment.
Insurance coverage concerns brought about by The Patient Protection and Affordable
Care Act (PPACA) (which was fully implemented in 2014). The insurance mandate in the
PPACA was expected to substantially increase SUD treatment utilization (Abraham, et al.,
2017). Forty million uninsured individuals were expected to gain access to an array of health
services with congressional approval of the ACA (Garfield, et al., 2019). In 2017, however,
27.4 million people remained without insurance coverage. At that time, approximately 18.7
million individuals had a SUD, 46.6 million had a mental health disorder, and 8.5 million had
both (McCance-Katz, 2018).
Public Assistance
Increases in SUD treatment associated with receiving public assistance was reported in
studies that examined factors associated with the past year’s substance use treatment, among
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adolescents, adults, and individuals ≥ 12 years old (Haughwout, et al., 2016; Romo, et al., 2018;
Wu, et al., 2011; Wu, et al., 2016).
Stigma
Stigma was defined as both a social and psychosocial process initiated by nonmarginalized individuals to create exclusion (Ahern, et al., 2007). Marginalized individuals
perceived their exclusion as a negative stereotype and internalized their perceptions. Research
suggested that stigmatization may result in attempts to hide drug use. Ali and colleagues (2017)
definition of stigma “as not receiving treatment because neighbors would have a negative
opinion, or the individual did not want others to know, or thought it would have a negative effect
on his or her job” exemplified the actions taken by marginalized individuals to evade being
stigmatized. Findings from studies that investigated stigma, showed an adverse association with
SUD treatment among young adults who used prescription painkillers non-medically (Ali, et al.,
2017; Liebling, et al., 2016; Novak, et al., 2019).
Needs Characteristics Associated with Treatment Utilization
Self-Reported Health Conditions
Health condition was described as a population need characteristic which played a role in
treatment utilization. This population characteristic relating to an individual’s self-reported
health was minimally addressed in studies found. A single study reported that in the adult
population, individuals with good health and having OUD were more likely to use OUD
specialty treatment more than those with excellent or poor health (Romo, et al., 2018).
Treatment Utilization Among Adolescents with OUD
Scientific knowledge reported on OUD treatment utilization among adolescents was
important for the current analysis. Data analyzed for the years 2016-2017, showed that 3.1% of
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adolescents in the U.S. misused opioids compared to 7.3% of young adults (Bose, et al., 2017).
Even though rates are lower for the adolescent group than the young adult group, adolescents
eventually became young adults and had new and different characteristics that influenced their
utilization of OUD treatment. Conflicting results were shown by Wu, et al., 2011 and
Haughwout, et al. 2016 relating to treatment utilization and perceived need among adolescents.
Wu and colleagues (2011) reported that adolescents were less likely to perceive a need for OUD
treatment. Haughwout and colleagues (2016) found that perceived need increased SUD
treatment, as did parent communication about the dangers of substance use.
Comorbidities and Other Substance Use Associated with Treatment Utilization
Comorbidities and concurrent substance use have contributed to increased OUD
treatment in adolescents (Haughwout, et al., 2016; Wu, et al., 2011). The inverse association
was shown in Wu and colleagues’ (2016) study among adults. Wu, and colleagues (2011)
examined adolescents in a longitudinal study. Haughwout, et al., 2016 study had a larger
longitudinal set. Wu et al. (2016) findings were also derived in longitudinal findings. Additional
associations found to exist between other predisposing, enabling and needs characteristics among
young adults, older adults and adolescents are detailed in Table 5.
Summary
Previous studies provided evidence that demographics, health beliefs, social structure,
sexual orientation, childhood characteristics, enabling characteristics (personal/family resources,
community resources), and needs characteristics (perceived health) were associated positively or
negatively with SUD treatment utilization. The focus of these prior studies was on the
adolescent and the adult (> 25 years old) population. OUD was minimally addressed.
Extrapolating knowledge from prior studies which can be translated to young adults’ treatment
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utilization for OUD was difficult. Further, studies synthesized, lacked, or marginally produced
scientific knowledge on the association of the ABM broad array of population characteristics to
treatment utilization among young adults with OUD in the U.S. Young adults have a greater
need for OUD treatment based on their high prevalence of OUD compared to adults > 25 years.
For these various reasons, the need for the current analysis was necessary.

38

TREATMENT UTILIZATION FOR OPIOID USE DISORDER
Chapter 3: Methods
Research Design
The study design was a secondary analysis of a subset of data extracted from the primary
dataset: The 2017 NSDUH (SAMHDA, 2017) dataset.
Primary Study Data Source
The 2017 NSDUH dataset (SAMHDA, 2017) was the U.S.’s primary source of national
estimates on the use of alcohol and illicit drugs, SUDs, behavioral/mental health and substance
use treatment in 2017 (Bose, et al., 2017). SAMHSA used DSM-IV in determining survey
participants’ SUD status (Bose, et al., 2017). The dataset contained data pertinent to ABM
population characteristics (predisposing, enabling and needs characteristics), which were posited
to associate to treatment utilization. These data were used to examine the research question for
this study: What are the predisposing, enabling, and needs characteristics as posited in the
Andersen Behavioral Model that are significantly associated with treatment utilization among
young adults with opioid use disorder in the United States?
Participants in the 2017 NSDUH included U.S. civilians who were noninstitutionalized,
and residing within the U.S. (Bose, et al., 2017). Participants were residents of households
(including civilians living in housing on military bases), or individuals in non-institutional group
quarters (shelters, boarding houses, college dormitories, migratory workers’ camps, halfway
houses), or homeless individuals with no permanent address but housed in shelters or single
rooms in hotels. Forty-eight contiguous states, Hawaii, and Alaska were represented, with a
small proportion (approximately 3%) of the U.S. population excluded. The excluded were
members of the active-duty military, individuals in institutional group quarters (long-term care
hospitals, institutional group quarters like prisons/jails, nursing homes, mental institutions), and
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homeless individuals with no permanent address and not housed in a shelter). Participants were
derived from 6,000 area segments that vary in size according to the state.
Primary Study Data Collection
The procedure used to select participants for the 2017 NSDUH involved visits by field
interviewers (FI) to sampled addresses (NSDUH, 2017b). In 2017, the quarterly design of the
survey required FIs to visit dwelling units (DUs) at each sampled address, to determine the
eligibility of the DU, to list individuals at the DU’s address, to select the sample of individuals to
be interviewed (if any), and to conduct interviews. A staff of approximately 650 FIs were
maintained for screening of possible participants. During the screening interview, FIs obtained
information on other DUs on the property. Any missing DU on the original DU list was included
in the sample.
The FIs used handheld computers to record results of the DU screening process and to
select the sample of for interviewing (NSDUH, 2017b). The handheld computer had computing
abilities and utilized parameters specified for each area segment, in combination with a random
number to determine sampled addresses. Each quarter, small reserve samples were held back so
that the assigned sample size could be adjusted, as needed, during the data collection process.
During quarterly intervals, the survey’s progress was monitored by the state.
A total of 68,032 computer-aided interviews (CAIs) were obtained for the 2017 NSDUH
(NSDUH, 2017b). The weighted screening response rate was 75.08% and the weighted
interview response rate for the CAIs was 67.12%. Throughout the screening process, anonymity
and privacy of participants were protected by separating identifying information from survey
responses. Compliance with federal laws relating to privacy was made known to participants.
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Additionally, privacy concerns, project descriptions, and frequently asked question were made
available on an NSDUH public information website.
The survey data collection tool utilized in the 2017 NSDUH, was an audio computerassisted self-interviewing (ACASI) system. This tool provided participants with a highly private
and confidential environment to answer questions. This environment was created to increase the
level of honest reporting of drug use behaviors. Survey answers to sensitive questions were
gathered through the ACASI system. During the ACASI portions of the interview, participants
listened to prerecorded questions through headphones and entered responses directly into a
computer without FIs having knowledge of answers. At the conclusion of the ACASI section,
the interview returned to the computer-assisted personal interviewing mode with the FI asking
the participants questions and entering the responses into the laptop. Each participant who
completed a full interview was compensated $30 in cash.
Primary Study Dataset Validation Procedures
The 2017 NSDUH questionnaire was used to collect cross-sectional data. In prior data
collection surveys, the possibility of participants misunderstanding survey questions and the
effects of field were recognized as possible problems with data collection (SAMHSA, 2010a).
To address these problems, the reliability and consistency of past and current surveys were
tested in reliability studies involving re-interviewing of the survey’s participants. In the
reliability studies, the same survey was used with a subset of participants. The aim was to
obtain a direct measure of the response variance, to evaluate the quality of the surveys and to
document the findings of the evaluation, to assist users of the survey, in their interpretation and
uses of findings from the surveys. Questions that did not score high on the studies’ reliability
measures were identified, tested, and improved.
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Current Study (Secondary Analysis) Data Source
A subset of the primary data source, the 2017 NSDUH dataset (SAMHDA, 2017), served as
the data source for this study. The inclusion criterion for selecting the study’s sample was all
survey participants in the age group 18 - 25 years old AND with a diagnosis of OUD. The
exclusion criteria for sample selection were all survey participants less than 18 years old or
greater than 25 years old or in the 18 - 25 years old age groups without a diagnosis of OUD.
Participants’ OUD status was contained in the dataset as the dichotomous variable,
OPINMYR. A participant’s OUD status was determined by SAMHSA using the DSM-IV
criteria (Table 1). OUD was attributed to the use of heroin and/or misuse of prescription
opioids in the past year. The subset of data extracted for this study totaled 1,021 survey
participants from the primary data source.
Variable Measurement
The variables in the study were organized according to the population characteristics in
the traditional and vulnerable domains described in ABM. The model posited that treatment
utilization (a health behavior) was associated with an individual’s predisposing characteristics
(demographics, health beliefs, social structure, sexual orientation, childhood characteristics),
enabling characteristics (personal/family resources, community resources), and needs
characteristics (perceived health; Gelberg, et al., 2000).
This study examined selected predisposing, enabling, and need characteristics which may
be associated with treatment utilization (Table 6).
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Table 6
List of the predisposing, enabling, and need characteristics
Predisposing
Demographics

Enabling
Personal/Family Resources

Age

Insurance

Gender

Income

Marital status

Parent communication

Veteran/Military status

Public assistance program

Health Benefits
Perceived need
Social Structure

Need
Perceived Health
Self-reported health condition

Community Resources
Residence location
Stigma

Ethnicity
Education
Employment
Household size
Sexual Orientation
Childhood Characteristics
Homelessness
Arrest history
Mental illness
Other substance use

Predisposing Characteristics. Predisposing characteristics posited in the traditional
domain of the ABM and extracted from the 2017 NSDUH dataset included (Table 7): age,
gender, marital status, veteran status, perceived need, ethnicity, education, employment, and
household size. In the vulnerable domain of the ABM, sexual orientation, homelessness, arrest
history, mental illness, and other substance use were extracted.
Enabling Characteristics. Enabling characteristics examined in this study: insurance,
income, parent communication, residence, stigma, and participation in public assistance
program. Details of each variable are provided in Table 7.
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Table 7
Data Type and Imputed/Recoded Status of Covariates Analyzed in This Study
Covariates
Type
Imputed /
NSDUH selected data to measure the study’s variables
Recoded
Demographics
Age
Gender
Marital status
Veteran/Military
status

Categorical
Dichotomous
Dichotomous
Dichotomous

No/Yes
No/No
Yes/Yes
No/No

The age in years of the survey’s participants (age values: 18, 19, 20, 21, 22, 23, 24, 25 years).
Male or female.
Married or not married (widowed, divorced, separated, never married).
Reserved or retired/separated/retired from active duty.

Dichotomous

Yes/Yes

Perceived need was obtained from the question: during the past 12 months, did you need treatment or
counseling for your use of prescription pain relievers?

Social structure
Race/ethnicity

Categorical

Yes/Yes

Education

Categorical

Yes/Yes

Race/ethnicity was obtained based on seven categories: non-Hispanic White, non-Hispanic Black/African
American, non-Hispanic Native American/Alaska Native, non-Hispanic Native Hawaiian/Pacific Islander,
non-Hispanic Asian, non-Hispanic mixed race, and Hispanic.
Education level was provided from the following choices: grade levels 5 through 10, grade 11/12 completed
with no diploma, high school completed with GED, some college credits (no degree), associate degree, or
college graduate/higher.

Categorical
Categorical
Categorical

Yes/Yes
Yes/Yes
No/No

Employment categories: employed full time, employed part time, unemployed, other (not in the labor force).
Household size was provided from the following choices: 1, 2, 3, 4, 5, 6 or more.
Sexual orientation was provided from the following choices: heterosexual/straight, lesbian/gay, or bisexual.

Categorical
Dichotomous

Yes/Yes
No/No

Resident location was classified as large metropolitan, small metropolitan, or non-metropolitan.
Values to the following questions determined stigma: (a) did not get treatment because treatment might cause
neighbors to have negative opinion? (b) Did not get treatment because treatment might have negative effect on
job? (c) Did not get treatment because did not want others to know?)

n/a
Dichotomous
Categorical

n/a
No/No
Yes/Yes

Variable not made available in the 2017 NSDUH dataset
Arrest history refers to being taken into custody, processed by the police or a court representative, even if
released.
Mental illness was any mental illness characterized as absent, serious, moderate, or mild.

Dichotomous

Yes/Yes

Other substance abuse in the 2017 NSDUH dataset was based on DSM-IV criteria.

Health benefits
Perceived need
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Employment
Household size
Sexual orientation
Community Resources
characteristics
Resident location
Stigma

Childhood
characteristics
Homelessness
Arrest history
Mental illness
Other substance
use
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Table 7
Data Type and Imputed/Recoded Status of Covariates Analyzed in This Study
Covariates
Type
Imputed /
NSDUH selected data to measure the study’s variables
Recoded
Personal/family
resources
Insurance coverage
Income
Parent
communication

Categorical
Categorical

No/Yes
Yes/Yes

Categorical

No/No
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Public assistance
Dichotomous
program
Perceived health
Self-reported health Categorical
condition
Outcome variable
Treatment
Dichotomous
utilization

Insurance coverage was defined as private / public (Medicaid) or insurance from special providers for the
military.
Measures total family income categorized as < $20,000 or $20,000 - $49,000 or $50,000 - $74,999, $75,000 or
more.
Parent communication is described as talking to at least one parent about the dangers of tobacco, alcohol, or drug
use. Parents was either one’s biological, adoptive, or stepparents or adult guardians -- whether or not they live
with them.

Yes/Yes

Encompass the following government program: supplemental security income, food stamps, cash assistance, and
non-cash assistance.

No/No

Self-reported health condition can be reported as excellent, very good, good, fair, or poor.

No/Yes

Treatment utilization was based on a survey participant’s receipt of treatment in the past year.
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Need Characteristics. The need characteristic in the vulnerable domain of the ABM,
extracted from the 2017 NSDUH dataset and examined in this study was the self-reported health
condition of the survey participant.
Special Measurement Cases. The variables perceived need and stigma were measured
by participants’ responses to specific survey questions. The use of these questions to analyze
perceived need and stigma was consistent with other studies and/or based on recommendations
from the 2017 NSDUH: Methodological Summary and Definitions (MSD; Ali, et al., 2015;
Romo, et al., 2018; SAMHSA, 2018b; Stringer & Baker, 2018). The MSD was a report that
summarized methods and other supporting information that were relevant to estimates of
substance use.
The following 2017 NSDUH questions measured perceived need: During the past 12
months, did you need treatment or counseling for your use of prescription pain relievers?
During the past 12 months, did you need treatment or counseling for your use of heroin?
Stigma was analyzed in this study by the following 2017 NSDUH questions: Did not get
treatment because treatment might cause neighbors to have negative opinion? Did not get
treatment because treatment might have negative effect on job? Did not get treatment because
did not want others to know?
Treatment Utilization. Treatment utilization, the outcome variable in this study, was
based on a survey participant’s receipt of treatment in the past year. In the 2017 NSDUH, the
reporting of treatment status in the past year as “unknown” by a survey participant, was
interpreted as no treatment received for illicit drug use (NSDUH, 2017b).
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Dataset Preparation
Two inclusion criteria (age 18 - 25 years and with a diagnosis of OUD) guided the data
extraction for this analysis. Utilizing the Statistical Package for the Social Sciences (SPSS)
Version 26, participants in the age group, 18 - 25 years old (CATAGE = 2) were filtered from
the 2017 NSDUH dataset (SAMHDA, 2017). This initial filtered group was all young adults.
The young adults’ OUD status, contained in the dataset as the dichotomous variable, OPINMYR,
was filtered from this initial group to extract those cases positive for OUD (OPINMR = 1). With
this young adult subset, data integrity checks were performed on all variables defined in the
ABM and relevant to the study, to ensure that the data were appropriate for analysis and fit
within the parameters defined for each variable. All selected variables were coded numerically
in the data analysis.
As part of the dataset preparation, a collapsing of variables was performed to facilitate
data analysis modeling. Some covariates in this study contained a range of values that had large
variability but small n. The covariates were collapsed into interval values and recoded into a
dummy variable. The values for the variable EDUCATION, for example, were coded as one for
fifth grade or less, two for sixth grade, three for seventh grade, four for eighth grade, followed by
similar numerical sequencing for other grade levels. The EDUCATION variable was analyzed
as a categorical variable. Homer and colleagues (2013) explained that the collapsing of levels
maintains the structure of the covariate, maintains any relationships to the outcome, with a
clearer picture of associations emerging.
Each multiple level covariate (including multiple level dummy variables) with k levels
was further manipulated by creating k - 1 dummy variables, to facilitate examination of
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associations between covariates and the outcome variable (treatment utilization). One k level
served as the baseline. The other k -1 dummy variables took on one of two values. Further,
dichotomous variables were standardized to two discrete values (0 = No, 1 = Yes) to facilitate
estimation of odds ratio generation in the logistic regression model.
Covariates utilized in this study were not expected to contain missing data (NSDUH,
2017b). Missing values in variables not analyzed in this study were numerically coded in the
2017 NSDUH dataset (NSDUH, 2017b). The numerical values 85, 94, 97, 98 and 99 in the
primary data source were used to represent bad data, don’t-know responses, refused, blanks and
legitimate skips. Legitimate skips referred to instances where a survey participant, skipped a
question not relevant to him/her (veteran/military status). In some cases, variables with missing
values were statistically imputed and recoded (Table 7) with valid response categories by
SAMHSA. Imputation procedures were developed specifically for the NSDUH (NSDUH,
2017).
Beginning in 1999, the predictive mean neighborhood (PMN) method for imputation was
implemented and was used for most variables in the national survey for drug use and health
(NSDUH, 2017). In 2015, the modified predictive mean neighborhood (modPMN) imputation
method was implemented for a subset of drug variables (CBHSQ, 2019). The predictive mean
neighborhood method combined two commonly used imputation methods: non-model-based
nearest neighbor hot deck (NNHD) and a modification of the model-assisted predictive mean
matching (PMM) method, which matched a missing value to the observed value with the closest
predicted mean. The modification of the PMM allowed for application of the PMN method to
both discrete and continuous variables, individually or jointly.
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Data Validation
Frequency counts were performed and screened for errors. The age variable
(CATAGE = 2) in the filtered dataset, for example, contained a value ≥ 18 and ≤ 25. A crosstab
with a second age variable (AGE2) which contained single age and age range values (18, 19, 20,
21, 22-23, 24 - 25) validated the total number of young adults extracted via the CATAGE
variable. Verification of the dichotomous covariates gender, perceived need, other substance
use, homelessness, arrest history, mental illness, OUD status, public assistance program and
receipt of treatment was performed by screening for values (one representing a yes response and
zero or two representing a no response). The categorical covariates (marital status,
veteran/military status, ethnicity, education, employment status, household size, sexual
orientation, income, residence, insurance, self-reported health) had more than two value levels
and were screened for their predetermined values. The values for the questions that determined
stigma (Did not get treatment because treatment might cause neighbors to have negative
opinion? Did not get treatment because treatment might have negative effect on job? Did not get
treatment because did not want others to know?) were also verified for their predetermined
values. These questions were selected based on previous research which utilized the NSDUH
data to examine treatment utilization and stigma (Stringer & Baker, 2018).
Total counts generated for each covariate were verified. The total counts reflected the
total number of cases filtered from the primary data source, the 2017 NSDUH dataset
(SAMHDA, 2017). The cumulative count of a specific variable was equivalent to the total
number of cases meeting the inclusion and exclusion criteria for the data records extracted for
the analysis. Further, the data values for each covariate containing multiple levels (sexual
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orientation could be heterosexual or straight or lesbian or gay or bisexual) were equivalent to the
nominal values specified in the survey codebook (referential integrity check). All variables
utilized in the analysis passed the referential integrity check.
Data Analysis Plan
The latest version of SPSS (v. 26.0) was used for the statistical analysis. The data
analysis was conducted in three phases. In the first phase, descriptive statistics, including
frequencies were calculated for all study variables. This phase allowed for the exploration of
covariates on the outcome variable without adjusting for any covariates.
The second phase of data analysis was a bivariate analysis. Specifically, a chi-square
analysis to identify which covariates are associated with the outcome variable, treatment
utilization (yes/no) at a statistically significant level (p < .05). Covariates that were significantly
associated with the outcome variable were included in the third phase of data analysis.
The third phase of data analysis incorporated a hierarchical binary logistic regression
model to examine the outcome variable as a function of all the covariates significantly associated
with the outcome variable in the bivariate analysis (Phase 2). The covariates were entered into
the regression model in three blocks. The first step included a block of significant Phase 2
variables representing predisposing characteristics. The second and third steps added other
significant Phase 2 variables in blocks consistent with the structure of the ABM model. The
hierarchical binary regression model was examined for multicollinearity, goodness-of-fit (via the
Pearson χ2 goodness-of-fit statistic), and overall statistical significance. The relationships
between the individual covariates and the outcome variable were assessed through the odds ratio
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(including the 95% confidence interval), coefficient estimates, and the level of statistical
significance for that covariate/response variable association.

Assumptions Regarding the Data and Statistical Procedures
General assumptions. The general assumptions were that the participants’ responses to
survey questions were accurate and that there was a linear relationship between treatment
utilization and the covariates. Further, that the homogeneity of variance did not need to be
satisfied. The sample was also assumed to be sufficiently large for the goodness-of-fit, where
the heuristic rule was that not more than 20% of the expected counts are less than five.
Missing Data. Imputation and recoding processes were applied to certain variables as
part of the dataset preparation by SAMHSA. The variables utilized in this study from the 2017
NSDUH dataset did not contain missing data, except for data which was intentionally left blank
in this public use dataset.
Multicollinearity. The main test assumption addressed within the binary logistic
regression model was to assure that the level of multicollinearity between the covariates was
acceptable. Therefore, an analysis was conducted to assure that (variance inflation factor) VIF
values were close to the value 1.0 and not greater than 2.0, a conservative value.
Homoscedasticity, Linearity, Normal Distribution of Scores, Outliers. Binary logistic
regression did not assume homoscedasticity, linearity, a normal distribution of scores, or, as a
result, these assumptions were not tested. In addition, the 2017 NSDUH variables used in this
study were not continuous, but rather, categorical variables and contain data within a narrow
range. The undue influence of outlier data will therefore not be tested.
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Other Assumptions Associated with Regression. Omission of variables in the primary
dataset affected the interpretation of statistical results. The variables selected to study the
phenomenon in this study were accessible in the 2017 NSDUH and provided accurate feedback
on the phenomenon being studied.
Protection of Human Subjects
The research protocol for this study met the criteria for exemption, in accordance with
City University of New York (CUNY) HRPP Procedures: Human Subject Research Exempt
from IRB Review.
Summary
The aim of this chapter was to describe the data analysis plan necessary to analyze the
covariates in the conceptual model associated with treatment utilization among young adults with
OUD in the U.S. MOUDs have been described as the most successful treatment, but
pharmacological data were unavailable in NSDUH to investigate the MOUD usage associated
with predisposing, enabling, and needs characteristics. Barriers to the use of MOUD were
identified. A more comprehensive understanding of additional characteristics which may explain
OUD treatment utilization in this population was needed. This study used a broad populationbased behavioral model to identify characteristics associated with treatment utilization for OUD.
These characteristics were grouped into traditional and vulnerable domains and were modifiable
or non-modifiable. Identification of these characteristics, particularly those that were modifiable
guided the development and enhancement of treatment strategies.
Using descriptive and inferential statistics frequencies were generated. Covariates with a
statistical significance level (p < .05) through single predictor logistic regression analysis were
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identified. Multivariable analysis was conducted to examine treatment utilization as a function
of all the significantly related covariates at the bivariate level. Results of the analyses were
interpreted as they relate to the behavioral model that underpins this study. Goodness-of-fit was
assessed. Associations between covariates and the outcome variable were assessed through the
odds ratio, coefficient estimates, and the level of statistical significance for the
covariate/outcome variable relationship.
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Chapter 4: Results
The primary purpose of the proposed study was to determine the predisposing, enabling,
and needs characteristics, as defined by ABM, that are associated with treatment utilization
among young adults with OUD in the U.S. The four hypotheses were that:
1.

among young adults with OUD in the U.S., certain predisposing characteristics
(older age, female gender, never married, non-veteran/military status, perceive
need of treatment, White race/ethnicity, having less than a high school education,
not part of the labor force, parent communication, household size, nonheterosexual, homelessness, arrest history, co-occurring substance use disorders,
SUDs) are positively associated with treatment utilization.

2.

among young adults with OUD in the U.S., the enabling characteristics high
income, having insurance coverage, residing in a large metropolitan area, and
participating in one or more public assistance program are positively associated
with treatment utilization.

3.

among young adults with OUD in the U.S., the needs characteristic self-reported
health condition is positively associated with treatment utilization and

4.

among young adults with OUD in the U.S., the predisposing characteristic, mental
illness, and the enabling characteristic, stigma, are negatively associated with
treatment utilization.

The outcome of the first phase in testing these hypotheses was a descriptive analysis of the
study’s categorical variables of interest (Table 8).
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Table 8
Descriptive Analysis of Categorical Study Variables (n = 1,021)
n

Variable

%

Outcome variable
Received treatment for illegal drug use in the past year
Received treatment at specialty facility only
Received treatment at non-specialty facility only
Received treatment at specialty and non-specialty facilities
Insufficient data to classify facility type
Did not receive illicit drug treatment

12
10
55
8
936

1.2
1.0
5.4
0.8
91.7

85
936

8.3
91.7

Demographics
Age (years)
18
19
20
21
22 - 23
24 - 25

100
112
129
126
270
284

9.8
11.0
12.6
12.3
26.4
27.8

Gender
Male
Female

504
517

49.4
50.6

Marital status
Married
Divorced or separated
Never been married

76
13
932

7.4
1.3
91.3

4
14
1003

0.4
1.4
98.2

Received treatment – collapsed for inferential analysis
Yes
No
Covariates

Veteran/military status
In a reserve component
Now separated/retired from reserves/active duty
No military/veteran status
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Table 8
Descriptive Analysis of Categorical Study Variables (n = 1,021)
n

Variable

%

Health beliefs
Perceived need
During the past 12 months, did you need treatment or counseling for your use of prescription pain
relievers?
Yes
13
1.3
No
26
2.6
Refused/blank/legitimate skip
982
96.1
During the past 12 months, did you need treatment or counseling for your use of heroin?
Yes
5
No
8
Refused/blank/legitimate skip
1,008

1.4
1.1
98.5

Race/ethnicity
Non-Hispanic White
Non-Hispanic Black/African American
Non-Hispanic Native American/Alaskan Native
Non-Hispanic Native Hawaiian/Other Pacific Islander
Non-Hispanic Asian
Non-Hispanic More Than One Race
Hispanic

608
121
14
6
15
66
191

59.5
11.9
1.4
0.6
1.5
6.5
18.7

Highest level of education
Less than high school diploma
High school diploma/GED
Some college credit, but no degree
Associates degree
College graduate or higher

176
351
345
70
79

17.2
34.4
33.8
6.9
7.7

Employment status
Employed full time
Employed part time
Unemployed
Other (not in labor force)

444
215
153
209

43.5
21.1
15.0
20.5
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Table 8
Descriptive Analysis of Categorical Study Variables (n = 1,021)
n

Variable

%

Number of persons in household
One person in household
Two people in household
Three people in household
Four people in household
Five people in household
Six or more people in household

55
264
241
248
124
89

5.4
25.9
23.6
24.3
12.1
8.7

Sexual orientation
Heterosexual, that is, straight
Lesbian or gay
Bisexual
Don’t know/refused

816
42
151
12

79.9
4.1
14.8
1.2

Arrest history
Yes
No
Don’t know/refused

330
688
3

32.4
67.4
0.3

Mental illness
No past year mental illness
Past year mild mental illness
Past year moderate mental illness
Past year serious mental illness

539
156
123
203

52.8
15.3
12.0
19.9

Other substance use
Yes
No

966
55

94.6
5.4

Any health insurance
Yes
No

876
145

85.8
14.2
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Table 8
Descriptive Analysis of Categorical Study Variables (n = 1,021)
n

Variable
Family income
Less than $20,000
$20,000 - $49,999
$50,000 - $74,999
$75,000 or more
Resident location
Large metropolitan
Small metropolitan
Non-metropolitan

%

313
323
155
230

30.7
31.6
15.2
22.5

404
407
210

39.6
39.9
20.6

14
32
975

1.4
3.1
95.5

12
34
975

1.2
3.3
95.5

7
39
975

0.7
3.8
95.5

281
740

27.5
72.5

147
390
366
118

14.4
38.2
35.8
11.6

Stigma
Did not get treatment because treatment might cause neighbors to
have negative opinion
Yes
No
Refused/blank/legitimate skip
Did not get treatment because treatment might have negative effect
on job
Yes
No
Refused/blank/legitimate skip
Did not get treatment because did not want others to know
Yes
No
Refused/blank/legitimate skip
Public benefits
Yes
No
Self-reported health condition
Excellent
Very good
Good
Fair/poor
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The observations of selected ABM population characteristics derived from the descriptive
analysis is presented below.
Predisposing Characteristics.
Approximately half the sample was between the ages of 22 and 25 years old
(n = 270, 26.4%) and 24 - 25 years (n = 284, 27.8) of age, with approximately half of the sample
reported as female (n = 517, 50.6%). Most young adults’ marital status was, never been married
(n = 932, 91.3%). Additionally, almost the entire sample reported no military status (n = 1003,
98.2%). The perceived need variable showed approximately 95% refused, blank or legitimate
skip rate. The highest proportion of young adults with OUD were non-Hispanic White (59.5%).
The remaining young adults were Hispanic 18.7%, Non-Hispanic Black/African American
11.9%, and “other” 9.9%. Approximately two-thirds of the young adults reported their highest
level of education as high school diploma/GED (n = 351, 34.4%) or some college credit, with no
degree totaling n = 345 (33.8%). Most young adults were employed full time (n = 444, 43.5%),
with the unemployed (n = 153, 15%) and those not part of the labor force (n = 209, 20.5%)
accounting for one-third of the study sample. A small percentage (n = 55, 5.4%) of the young
adults reported only one person in their household. Almost the entire sample had a heterosexual
orientation (n = 816, 79.9%). Approximately one-third (n = 330, 32.4%) of the young adults
reported having an arrest history, with approximately half of the sample (n=539, 52.8%) having
no mental illness within the past year. A high percentage, almost 95% of the young adults,
reported other substance use in the past year (n=966, 94.6%).
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Enabling Characteristics.
Over three-quarters of the sample reported having health insurance (n = 876, 85.8%).
More than a half reported having private health insurance (n = 567, 55.5%). Approximately onethird of the young adults reported their family income as less than $20,000 (n = 313, 30.7%) and
nearly another third reported income of $20,000 - $49,999 (n = 323, 31.6%). Residence was
reported as large metropolitan (n = 404, 39.6%), small metropolitan (n = 407, 39.9%), or nonmetropolitan setting (n = 210, 20.6%). Stigma evidenced a refused, blank, or legitimate skip rate
of approximately 95% by the study participants. Approximately one-quarter of young adults
reported participating in one or more public assistance program (n = 281, 27.5%).
Needs Characteristic.
On a scale from excellent, very good, good, fair, to poor, most young adults described
their health as very good (n = 390, 38.2%) or good (n = 366, 35.8%). Only 14.4%, n = 147
reported excellent health condition and 11.6%, n = 118 reported fair/poor health condition.
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Bivariate Analysis
The results of the bivariate analysis are displayed in Table 9. The inclusion of covariates
in the regression model was based on the significance level, p < .05.

Table 9
Chi-Square Analysis of Treatment Utilization (yes/no) with Covariates (n = 1,021)
No treatment
Treatment
utilized
utilized
Variable
Age (years)
18
19
20
21
22 - 23
24 - 25

n

93
105
121
120
244
253

%

(93.0)
(93.8)
(93.8)
(95.2)
(90.4)
(89.1)

n

7
7
8
6
26
31

%

460
476

(91.3)
(92.1)

44
41

Veteran/military status
In a reserve component
Now separated/retired from
reserves/active
duty status
No veteran/military
Race/ethnicity
White
Black/African American
Hispanic
Other (Native American/Alaskan
Native, Native Hawaiian/Other Pacific
Islander, Asian, and more than one
race)

67
12
857

(88.2)
(92.3)
(92.0)

9
1
75

4 (100.0)
13 ) (92.9)
919 (91.6)

0
1
84

547
118
180
91

61
3
11
10

61

(90.0)
(97.5)
(94.2)
(90.1)

6.82(5)

.23

.21 (1)

.64

1.33(2)

.51

(8.7)
(7.9)

Marital status
Married
Divorced or separated
Never been married

p

(7.0)
(6.3)
(6.2)
(4.8)
(9.6)
(10.9)

Gender
Male
Female

X²(df)

(11.8)
(7.7)
(8.0)
.39 (2)

.82

9.72 (3)

.02

(0.0)
(7.1)
(8.4)
(10.0)
(2.5)
(5.8)
(9.9)
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Table 9
Chi-Square Analysis of Treatment Utilization (yes/no) with Covariates (n = 1,021)
No treatment
Treatment
utilized
utilized
Variable
Highest level of education
Less than high school diploma
High school diploma/GED
Some college credit, but no degree
Associates degree
College graduate or higher

n
158
316
319
66
77

%
(89.8)
(90.0)
(92.5)
(94.3)
(97.5)

n
18
35
26
4
2

%

417
202
127
190

(93.9)
(94.0)
(83.0)
(90.9)

27
13
26
19

52
247
213
230
118
76

(94.5)
(93.6)
(88.4)
(92.7)
(95.2)
(85.4)

3
17
28
18
6
13

269 (81.5)
667 (96.5)

504
140
110
182

(93.5)
(89.7)
(89.4)
(89.7)

35
16
13
21

881 (91.2)
55 (100.0)

62

.001

12.20(5)

.03

69.94 (1)

.001

5.03 (3)

.17

5.28(1)

.02

(6.5)
(10.3)
(10.6)
(10.3)

Other substance use
Yes
No

19.62 (3)

61 (18.5)
24 (3.5)

Mental illness
No past year mental illness
Past year mild mental illness
Past year moderate mental illness
Past year serious mental illness

.69

(5.5)
(6.4)
(11.6)
(7.3)
(4.8)
(14.6)

Arrest history
Yes
No (includes don’t know/refused)

1.48 (4)

(6.1)
(6.0)
(17.0)
(9.1)

Number of persons in household
One person in household
Two people in household
Three people in household
Four people in household
Five people in household
6 or more people in household

p

(10.2)
(10.0)
(7.5)
(5.7)
(2.5)

Employment status
Employed full time
Employed part time
Unemployed
Other (not in labor force)

X²(df)

85 (8.8)
0 (0.0)
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Table 9
Chi-Square Analysis of Treatment Utilization (yes/no) with Covariates (n = 1,021)
No treatment
Treatment
utilized
utilized
Variable

n

%

n

%

Sexual orientation
Heterosexual, that is, straight
Lesbian or gay
Bisexual
Don’t know/refused

747
40
138
11

Residence
Large metro
Small metro
Nonmetro

370 (91.6)
377 (92.6)
189 (90.0)

34 (8.4)
30 (7.4)
21 (10.0)

Any health insurance
Yes
No

801 (91.4)
135 (93.1)

75 (8.6)
10 (6.9)

Private insurance
Yes
No

522 (92.1)
414 (91.2)

45 (7.9)
40 (8.8)

Family income
Less than $20,000
$20,000 - $49,999
$50,000 - $74,999
$75,000 or More

289
293
145
209

24
30
10
21

(91.5)
(95.2)
(91.4)
(91.7)

(92.3)
(90.7)
(93.5)
(90.9)

69
2
13
1

.73 (3)

.87

1.26 (2)

.53

.45(1)

.50

.25(1)

.62

1.48(3)

.69

8.67(1)

.003

2.77 (3)

.43

(7.7)
(9.3)
(6.5)
(9.1)

35 (12.5)
50 (6.8)

Self-reported health condition
Excellent
Very good
Good
Fair/poor

8
31
36
10

(94.6)
(92.1)
(90.2)
(91.5)

p

(8.5)
(4.8)
(8.6)
(8.3)

Participated in one or more public assistance program(s)
Yes
246 (87.5)
No
690 (93.2)
139
359
330
108

X²(df)

(5.4)
(7.9)
(9.8)
(8.5)

Few covariates (race/ethnicity, employment status, household size, arrest history, other
substance use, participated in one or more public assistance programs) were significantly
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associated, p < .05, with treatment utilization. The covariate race/ethnicity reflected that
Black/African Americans (n = 3, 2.5%) had the lowest rate of treatment utilization relative to
White persons, Hispanic persons, and other races. White young adults (n = 61, 10.0%) had the
highest treatment utilization rate among all races/ethnicities, even though it was still quite low.
In the race/ethnicity category, other races, (n = 10, 9.9%) tended to utilize treatment more than
Hispanic and Black/African American young adults.
Regarding employment status, the unemployed young adults (n = 26, 17.0%) evidenced a
higher rate of treatment utilization relative to the employed (full time or part time) or those not in
the labor force. Young adults who reported having an arrest history (n = 61, 18.5%) showed a
higher rate of treatment utilization relative to those with no arrest history. The lowest rate of
treatment utilization was reported among a household size of one (n = 3, 5.5%) and a household
size of 5 (n = 6, 4.8%) relative to other household sizes of two, three four, or six plus persons.
Those who reported other substance use (n = 85, 8.8%), reported a higher rate of treatment
utilization relative to those who had not (n = 0, 0.0%). This variable, other substance use could
not be included in the multivariate model as there were zero young adults with no other
substance use and treatment utilization. Lastly, young adults’ participation in one or more public
assistance programs (n = 35, 12.5%) showed a higher treatment rate relative to those who did not
participate in one or more public assistance programs.
Multivariable Analysis
The results of the multivariable analysis are displayed in Table 10. The hierarchical
binary regression model examined the association of significant covariates (race/ethnicity,
employment status, household size, arrest history, participation in public assistance programs)
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with the outcome variable, treatment utilization. The model showed no evidence of
multicollinearity, as all VIF values were approximately 2.5 or lower. A VIF of 2.0 was
considered extremely conservative with 2.5 still classified as conservative (Field, 2009). The
overall regression model was statistically significant p < .001 and classified 92.0% of cases
correctly. Results from the final step (Step Three) of the regression model answered the research
question and supported or rejected the study’s hypotheses.
Table 10
A Hierarchical Binary Logistic Analysis Examining Treatment utilization (n = 1,021)
Variable

B (SE)

Wald X²

OR (95% CI)

p

Step 3
Race/ Ethnicity
White (Reference Group)
Black
Hispanic
Other

₋2.15 (.63)
₋.74 (.37)
₋.06 (.39)

11.56
4.08
.04

.12 (.03-.40)
.48 (.23-.98)
.95 (.43-2.00)

Unemployed (Reference Group)
Employed Full-time
Employed Part-time
Other (not part of labor force)

₋1.19 (.33)
₋1.05 (.39)
₋.56 (.36)

12.98
7.20
2.46

.30 (.16-.58)
.35 (.16-.75)
.57 (.29-1.15)

.001
.007
.12

Six or more people (Reference Group)
One person
Two people
Three people
Four people
Five people

₋.65 (.71)
₋.68 (.44)
.03 (.41)
₋.44 (.43)
₋1.24 (.56)

.84
2.38
.01
1.03
4.93

.52 (.13-2.11)
.51 (.22-1.20)
1.03 (.46-2.30)
.65 (.28-1.50)
.29 (.10-.87)

.36
.12
.94
.31
.03

History Arrest

1.82 (.26)

48.44

.45 (.27)

2.89

.001
.04
.85

Household Size

Participated in Public Assistance Program(s)

Step 1: Model = X²(11) = 44.23, p < .001.
Step 2: Model = X²(12) = 103.05, p < .001.
Step 3: Model = X²(13) = 105.88, p < .001.
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Hypothesis Testing
Hypothesis One. Hypothesis one stated that among young adults with OUD in the U.S.,
the predisposing characteristics (older age, female gender, never married, non-veteran/military
status, perceive need of treatment, White race/ethnicity, having less than a high school
education, not being part of the labor force, parent communication about the danger of tobacco,
alcohol or drugs, household size, non-heterosexual, homelessness, arrest history, other
substance use) are positively associated with treatment utilization.
The four covariates in hypothesis one, determined to be significantly associated with
treatment utilization (race/ethnicity, employment, household size, arrest history) in the
intermediary step were entered into the model in blocks reflecting the ABM’s structure of
predisposing, enabling and needs characteristics. Homelessness was not analyzed in the
intermediary step as the public use file contained no data for the covariate, homelessness. The
significant covariate, other substance use, significant in the intermediary step, was not entered
into the model as there were zero subjects in one of the categories (young adults who did not use
other substances and did not utilize treatment).
Findings showed that young Black adults were eight times less likely, and Hispanics were
two times less likely to utilize treatment compared to young non-Hispanic White adults. Young
adults who reported being employed were less likely to utilize treatment compared to young
adults who were unemployed. A young adult employed full-time was more than three times less
likely to utilize treatment while a part-time employee was nearly three times less likely to utilize
treatment compared to the unemployed young adult. Young adults not in the labor force did not
maintain a significant association with treatment utilization. Young adults residing in a five-
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person household were over three times less likely to utilize treatment compared to a young adult
residing in a six-person plus household. Young adults reporting an arrest history were more than
six times more likely to utilize treatment compared to those who did not have an arrest history.
Arrest history was positively associated with treatment utilization in step three of the model.
Hypothesis one was therefore partially supported.
Hypothesis Two. Hypothesis two stated that among young adults with OUD in the U.S.,
the enabling characteristics high income, having insurance coverage, residing in a large
metropolitan area, and being on one or more public assistance program(s) are positively
associated with treatment utilization. Being on one or more public assistance program(s) was
the only covariate in this hypothesis that remained significant in the intermediary step. In the
model however, this covariate did not remain significant. Hypothesis two was not supported.
Hypothesis Three. Hypothesis three stated that among young adults with OUD in the
U.S., the needs characteristic self-reported health condition is positively associated with
treatment utilization. In the intermediary step, this covariate was not significantly associated
with treatment utilization and therefore not entered in the model. Hypothesis three was not
supported.
Hypothesis Four. Hypothesis four stated that among young adults with OUD in the
U.S., the predisposing characteristic mental illness and the enabling characteristic stigma are
negatively associated with treatment utilization. In the intermediary step, mental illness was not
significantly associated with treatment utilization. Stigma was excluded from the intermediary
step. Hypothesis four was not supported.
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The Research Question
The research question formulated for this study was: What are the predisposing, enabling,
and needs characteristics as posited in the Andersen Behavioral Model that are significantly
associated with treatment utilization among young adults with opioid use disorder in the United
States? Step three of model showed that the ABM’s predisposing characteristics significantly
associated with treatment utilization were race/ethnicity, employment status, household size and
arrest history. These associations, except for arrest history were weak. The various levels within
the covariates with a significant association (race/ethnicity, employment status and household
size) were not all significant.
Interaction Effect
An interaction effect to examine age as a moderator of residence and treatment utilization
was added to the final model. Age did not moderate the association between residence location
and treatment utilization at a statistically significant level, B = .03, SE = .11, Wald X² = .06,
OR = 1.03, 95% CI [.83, 1.27], p = 81) within the limited power of testing.
Summary
This study focused on the ABM’s population characteristics (predisposing, enabling,
needs) to determine associations between selected characteristics and treatment utilization among
young adults with OUD in the U.S. Treatment utilization was examined in a regression model as
a function of all covariates with significant associations in the intermediate step. The results in
step three of the model were used to evaluate the statements made in the study’s hypotheses.
Two statistical analyses (bivariate analysis, multivariable analysis) were conducted to reveal a
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more limited set of covariates (race/ethnicity, employment status, household size and arrest
history) predicting treatment utilization.
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Chapter 5: Discussion
Most previous OUD treatment utilization studies focus on the adolescent or adult
population. Additionally, earlier studies did not examine the association of the multidimensional population characteristics in the ABM with treatment utilization, specifically among
the young adult population with OUD in the U.S. Extrapolating treatment utilization results
from previous studies to the young adult population with OUD is therefore difficult, making it
necessary to conduct this study. Other principal reasons for this study are the upward trend of
mortality rates, involving opioids misuse (NIDA, 2020). Additionally, young adults have a
higher prevalence of OUD and a greater OUD treatment need when compared to older adults.
Understanding treatment utilization among young adults with OUD in the U.S. is important too,
for planning strategies to address any deficiencies in treatment utilization among this population.
This study addresses treatment utilization in the understudied young adult population with OUD
in the U.S. It tests the association of treatment utilization with a broad array of demographics,
and social characteristics, personal/family resources and community resources posited in the
ABM.
The ABM characteristics consist of predisposing characteristics (age, gender, marital
status, veteran status, health belief, ethnicity, education, employment, family size, immigration
status, literacy, living conditions, sexual orientation), enabling characteristics (insurance,
income, residence, religion, self-help skills, social service resources, being on public assistance
program[s], transportation), and need characteristics (self-reported health condition, evaluated
health condition). Considering the propositions of the ABM, selected ABM characteristics are
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analyzed to determine their association with treatment utilization among young adults with OUD
in the U.S.
Treatment Utilization
Findings show that treatment utilization is low among young adults with OUD in the U.S.
within the past year. More than 90% of this study’s sample do not utilize treatment, although all
have a diagnosis of OUD in the past year. This finding could not be compared to the results of
similar studies as reports on treatment utilization specifically among young adults were not
found. Studies analyzing national data on treatment utilization in the past year among the U.S.
population, inclusive of young adults, report low rates of OUD treatment utilization (Becker,
et al., 2008; Romo, et al., 2018; Saloner & Karthikeyan, 2015; Wu, et al., 2016). Between 2000
and 2004, for example, less than 16% of the U.S. population with OUD, are reported as receiving
any treatment (Becker, et al., 2008). Most individuals 12 years and older who needed OUD
treatment, from 2010 to 2014 are reported as utilizing no treatment (Romo, et al., 2018). The
same observation is made in the period 2009 and 2013, with 21.5% of the U.S. population
reporting treatment use for OUD (Saloner & Karthikeyan, 2015).
These unchanging treatment patterns among the U.S. population may be explained by
systemic level or individual level factors. At the systemic level there are limitations placed on
the number of physicians, nurses, and other healthcare providers who can prescribe BUP
(Alderks, 2017; SAMHSA, 2019c; The President’s Commission, 2017; Thomas, et al., 2014).
The existence of office-based OUD treatment barriers (insurance pre-approval / reimbursement,
stigma, perceptions of “difficult” patients, and legal restrictions specific to sublingual BUP
prescribing) are systemic reasons (Andraka-Christou & Capone, 2018; Haffajee, et al., 2020).
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Healthcare providers unfamiliarity with the formulations of MOUDs are included (Haffajee,
2020).
At the individual level, young adults are unwilling or ready to stop using illicit opioids
(Liebling, et al., 2016). They fear negative opinions when others find out about their substance
use or have perceptions of being able to handle the problem on their own. Additionally, the adult
population (which includes young adults) with SUDs and comorbid conditions (mental illness)
tend to obtain mental health services rather than substance abuse treatment (Ali, et al., 2015;
Romo, et al., 2018). Further, whether a need is perceived for treatment or not, adults do not seek
treatment (Ali, et al., 2015; 2017). Homelessness affects OUD treatment utilization too
(Liebling, 2016). Liebling and colleagues (2016) reported a decreased likelihood of treatment
utilization with homelessness (Liebling, et al., 2016).
Associations of ABM Characteristics with Treatment Utilization
The analysis is performed on data extracted from a large, nationally representative
sample of individuals with SUDs in the U.S. The data do not allow for the analysis of all the
prospective factors associated with treatment utilization among young adults with OUD.
However, significant associations are found between the selected ABM characteristics and
treatment utilization for OUD. These associations provide valuable knowledge for policies
aimed at addressing treatment utilization for OUD among young adults in the U.S. The ABM
predisposing characteristic, arrest history is six times more likely to be associated with treatment
utilization. Race/ethnicity, employment status, and household size are less likely to be
associated with treatment utilization.
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Race/Ethnicity
Findings reveal that there are more non-Hispanic White young adults with OUD than
Black and Hispanic young adults. Prior studies confirm this finding (Liebling, et al., 2016;
Romo., et al., 2018; Saloner & Karthikeyan, 2015). Several reasons are suggested for the
differences based on race/ethnicity (Hoffman, et al., 2016; Netherland, & Hansen, 2016;
Pouget, et al., 2018). First, racial bias exists in the prescribing of pain medications for racial
minorities and in the perceptions of others’ pain (Hoffman, et al., 2016; Pouget, et al., 2018).
Healthcare providers rate Black persons’ (vs. white persons’) pain lower. This false belief, that
Black persons feel less pain than White persons contributes to racial disparities in pain
assessment and treatment, and consequently higher exposure to prescription opioids among
Whiter persons. Second, it has been reported that minorities have less access to prescription
opioids compared to White persons (Friedman, et al., 2019; Singhal, et al., 2016). This lack of
access to prescription opioids may also arise from the mistrust of the healthcare system based on
community-reported or individual experiences of racism (Smith, 2010). Such mistrust is not
surprising, considering revelations of unethical research practices (Tuskegee Syphilis Study, the
misappropriation of Henrietta Lacks's cells for research; CDC, 2021; Lucey, et al., 2009).
As in previous studies (Liebling, et al., 2016; Romo, et al., 2018; Wu, et al., 2016), this
study found that the Black/African American young adult utilized treatment less than Whites.
This may speak to the fact that Blacks are more likely to live in socially disadvantaged
communities, where there may be fewer facilities to provide access to all MATs for OUD
(Goedel, et al., 2020; Reboussin et al., 2015; Sampson, 2011; Wallace & Muroff, 2002).
Additionally, minorities may be less willing to pursue treatment due to the potential for child
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welfare involvement (CWIG, 2021). The Child Abuse Prevention and Treatment Act of 2016
and Family First Prevention Services Act of 2018 require states to have laws, policies, and/or
procedures requiring health-care providers involved in the delivery or care of infants to notify
child protective services if a child is identified as being affected by substance abuse, withdrawal
symptoms resulting from prenatal drug exposure or our occurrences of fetal alcohol spectrum
disorders.
Employment
Consistent with other studies relating to prescription drug misuse in the U.S. population
(Choi, et al., 2019; LeClair, et al., 2015; Romo, et al., 2018), this study finds that most young
adults with OUD in the U.S. are employed at least part time. Additionally, this study finds that
employed young adults utilize treatment less than unemployed young adults and those not in the
work force (includes students, persons keeping house or caring for children full time, retired or
disabled persons, or other persons). This finding is confirmed among a statewide sample of
young adults, among the over 12 years old population and among an adult population (Liebling,
et al., 2016; NSDUH, 2017b; Romo, et al. 2018). The employed are often covered by employermandated insurance plans (IRS, 2020). Many employer plans establish coverage for SUD
treatment as mandated by the ACA. However, a full array of substance abuse treatment benefits
(residential treatment, all FDA approved MOUDs) are not covered (NCASA, 2017).
Additionally, with difficulties in accessing timely treatment due to delays in obtaining
insurance authorizations, and excessively high out-of-pocket costs (copayments), the motivation
to seek treatment is minimalized, leading individuals with SUD to forego treatment. For
individuals with limited income (unemployed, those not in the labor force), Medicaid and other
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affordable state plans provide a range of substance abuse treatment options (inpatient and
outpatient treatment, pharmacologic treatment for opioids; CMS, 2016; Healthcare.gov, n.d.).
Household Size
Household size is defined as a count of the number of family members greater than or
equal to 12 years old in the household (NSDUH, 2017). Most young adults (94.5%) do not live
alone. Young adult living in a household with five persons is over three times less likely to
utilize treatment compared to a six-person plus household. Probing further to obtain a clearer
understanding of the association of household size with treatment utilization is not
accomplishable as this is an epidemiological study, that is retrospective. In contrast, a qualitative
or mixed method study could have provided that information. The household size association
with treatment utilization in step three of the regression analysis is partially explained by
evidence in other studies which indicate that the treatment preference of individuals with OUD is
to have family involvement in their substance use treatment (Andraka-Christou, et al., 2021;
Ariss, et al., 2020; Hogue, et al., 2018).
Arrest History
Young adults with an arrest history are more likely to utilize treatment for OUD. Other
studies support this finding (Nam, et al., 2016; Romo, et al., 2018; Choi, et al. 2019).
Individuals with SUDs are often ordered to treatment programs (alternative-to-prison,
community-based supervision, community-based treatment, prison-based) following an arrest
(Andraka-Christou, et al., 2020; Belenko, et al., 2013; NADCP, 2015). This may be to satisfy
release considerations. Becoming involved in a treatment program too, may also reflect a
person’s own decision to show the courts that they are making positive changes.
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Other ABM Characteristics
The analysis of national data prior to 2017, show that more males than females in the
adolescent and young adult population misuse opioids (Hudgins, et al., 2019). Wu and
colleagues (2016), analyzing 2005-2013 national data, make the same observation among the
≥ 12-year-old population. This contrasts with findings in this study which showed that the
female and male genders have equal prevalence of OUD. This equalizing of prevalence of OUD
rates among men and women, indicates an obvious rise in OUD among young adult women.
This occurrence is explained by reports in other studies (Compton, et al., 2016; Koons, et al.,
2018). Compton and colleagues’ (2016) review article reports shifts in demographic
characteristics associated with heroin use, an illicit opioid. Firstly, they report increase rate of
heroin usage among young adults, in both genders, but more among women than among men
(Compton, et al., 2016). This evidence is based on the analysis of data from NSDUH and
National Vital Statistics from 2002-2013. Koons and colleagues (2018) literature commentary
indicate that women more than men are more likely to be prescribed opioids (based on the
analysis of data from the 1999-2012 National Health and Nutrition Examination Survey).
Women are therefore placed at higher risk for opioid misuse and therefore subsequent disorder.
Further, women are reported to have higher prevalence of gender-based sexual and
domestic violence with ensuing psychological effects which increase vulnerability to opioid
misuse (D’Inverno, et al., 2019; Koons, et al., 2018). D’Inverno and colleagues (2019) analyzed
data on intimate partner violence, sexual violence and stalking victimization of adult women and
men (≥ 18 years) from the U.S. National Intimate Partner and Sexual Violence Survey.
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As it pertains to the ABM characteristic, educational status, most young adults who do
not utilize treatment, only attain a high school diploma/GED or some college credit, but no
degree. This finding is consistent with studies conducted prior to 2017 or studies which analyzed
data prior to 2017, examining the young adult and the adult populations’ prescription drug
misuse and/or SUD treatment utilization (Liebling, et al., 2016; McCabe et al., 2018; Romo,
et al., 2018). It may be too, that some young adults have no interest in pursuing higher education
at this developmental stage of their lives. LeClair and colleagues (2015) report that young
adulthood is marked by experimentation. Experimentation at the young adult stage motivates
risk behaviors (substance use) that change the educational trajectories of young adults.
Young adults reporting treatment utilization has either mild, moderate, or serious mental
illness. Previous analysis of adults ≥ 18 years in a national dataset shows similar findings
(Romo, et al., 2018). It is not surprising that mental illness occurs with OUD. OUD is a
subgroup of SUD, and SUD have been reported to occur in conjunction with mental
comorbidities (Ali, et al.,2015; Butler, et al., 2017; Defoe, et al., 2019; Haughwout, et al., 2016;
Jones, et al., 2017; Rodriguez-Sejias, et al., 2017; Romo, et al., 2018; Wu, et al., 2016;
Tragesser, et al., 2013). Additionally, individuals with co-occurring SUDs and mental illness
may have different patterns of treatment (Novak, et al., 2019). Some may receive substance use
treatment. Others may obtain mental health services rather than substance use treatment
(Ali, et al., 2015). Yet still, some may not be well served within the existing health care system
where SUD and mental illness treatment are not integrated or coordinated appropriately.
A noteworthy finding is that young adults residing in small and large metropolitan areas
are less likely to utilize treatment for OUD compared to those in rural/non-metropolitan areas.
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This is unexpected as The President Commission’s 2017 report states that treatment utilization is
less prevalent in rural (vs metropolitan) areas due to barriers like the unavailability of MOUDs
and DEA-waivered physicians to treat OUD. This reversal may be due to NIDA and other
federal agencies funding of several initiatives to offer SUD services in rural areas, with state and
local communities developing best practice responses which are implemented by public health
systems (HRSA, 2021, NIDA, 2017a). The National Center for Health Statistics, August 2019
Data Brief No. 345 confirms this reversal (Hedegaard, et al., 2019). It may be too, that these
young adults, diagnosed as having an OUD, may not know that they have a substance problem.
Thus, treatment utilization is not sought.
Delimitations
This study is delimited by the variables present in the 2017 NSDUH dataset selected for
this study (SAMHDA, 2017). Further, the individuals in the surveyed population were defined
as U.S. civilians who were noninstitutionalized and residing within the U.S. (Bose, et al., 2017).
Participants were residents of households (including civilians living in housing on military
bases), or individuals in non-institutional group quarters or homeless individuals with no
permanent address but housed in shelters or single rooms in hotels (Bose, et al., 2017). A total of
56,276 individual survey responses were collected of which 13,840 were determined to be young
adults possibly eligible for the study. Members of the active-duty military, individuals in
institutional group quarters (long-term care hospitals, institutional group quarters like
prisons/jails, correctional facilities, nursing homes, mental institutions), and homeless
individuals with no permanent address and not housed in a shelter were excluded.
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Limitations
Because of the retrospective nature of a secondary analysis, study participants could not
be probed for additional information to provide a clearer understanding of associations. Lack of
variables of interest, blanks/refused responses, or legitimate skips rates > 87% in the NSDUH
dataset makes it impossible to obtain findings on (a) differences in treatment utilization among
young adults (who sought treatment vs those who did not seek treatment) as it relates to specific
MOUD, (b) the interaction effect of MOUDs and age (c) the interaction effect of treatment
physical location and residence location, (d) treatment utilization association with treatment
access, or (e) treatment utilization association and medical comorbidities.
SAMHSA utilizes one-time interviews, self-reports, and computer-assisted
questionnaires to collect data for the 2017 NSDUH dataset (NSDUH, 2017b). These data
collection methods unintentionally introduce bias resulting from under-reporting, over-reporting,
or invalid/inconsistent responses (SAMHSA, 2018a). The value of the data is, therefore,
dependent on the honesty, memory recall, and accuracy of the survey participant. Further, with
one-time interviews, the data collected, provides an overview of possible characteristics that may
be associated with treatment utilization at a specific point in time rather treatment utilization
changes over time.
Actions were taken by SAMHSA to mitigate biases (SAMHSA, 2018a). The use of an
audio computer-assisted data collection tool provided participants with a vastly private and
confidential setting in which to respond to questions. The goal was to increase the level of
honest reporting of drug use behaviors. Further, answers provided to sensitive questions were
gathered through a computerized data collection tool, without interviewers having knowledge of
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answers. With respect to one-time interviews, SAMHSA had produced datasets on drug use and
health on a yearly basis, though not necessarily interviewing the identical individuals each year.
Inconsistent responses from survey participants were addressed by deterministic editing or by
use of imputation methods. Deterministic editing to correct inconsistent responses is appropriate
when a unique association exists between independent variables and covariates (determining
gender from relationships [son, daughter] to head-of-household). Unambiguous determinations
are not always possible (gender from the cousin relationship), in such cases, the inconsistent
response was replaced with statistically imputed data.
Implications
Practice and Policy
This study identifies various ABM characteristics (race/ethnicity, employment status,
household size and arrest history) that are associated with treatment utilization among young
adults in the U.S. Employment status and household size may not be directly modifiable to
affect treatment utilization. A young adult with OUD, who is employed (part time or full time)
should not face insurance barriers to treatment utilization. Insurance options that provide
unlimited substance use treatment visits and affordable copayments for substance use treatment
should become part of employers’ and government’s insurance offerings. Tax incentives can be
utilized to persuade employers to comply.
The household size of a young adult may not be directly modifiable. However, with the
implication that individuals with OUD prefer to have family involvement in their substance
treatment (Andraka-Christou, et al., 2021; Ariss, et al., 2020; Hogue, et al., 2018), it may be
necessary to place young adults with no family support, into special environmental settings
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where they are motivated to utilize treatment by healthcare providers, counselors, and their peers
in similar situations.
NIH endorses various practical treatment-related strategies address opioid overdose
(NIH, 2018). Table 11 lists these strategies.
Table 11
NIH Treatment-Related Strategies for Treating Opioid Use Disorder
• 911 Good Samaritan Laws to prevent bystanders from putting themselves at risk of
arrest when seeking emergency care for an opioid overdose
• academic detailing to help healthcare providers use best practices
• eliminating prior-authorization requirements for MOUDs
• initiating BUP-based therapies in emergency departments for untreated OUD
• screening for fentanyl in routine clinical toxicology testing
• targeted NAL distribution
• use of MOUDs

Results of this study should inform the assessment of these NIH strategies to determine
their effectiveness in contributing to treatment utilization among young adults. The use of
MOUDs should be made equally accessible to Black, Hispanic, non-Hispanic Asian persons
including other persons, who are less likely to utilize OUD treatment compared to White
persons. In addition, identifying minority areas underserved by existing OUD treatment
facilities, on a state-by-state basis, may be necessary. The identification of underserved minority
areas may inform policy makers on high need areas requiring resources for MOUDs.
This study’s findings show that young adults are more likely to utilize treatment, if they
have an arrest history. Having an arrest history should not be the gateway to OUD treatment for
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young adults. It may however be prospectively modifiable to prevent young adults from being
arrested or re-arrested for misuse of opioids or opioid-related infractions. Strategies that
implement interventions, policies, and practices (a) prescription drug monitoring programs
(Bohnert, et al., 2018), (b) prescribing of non-pharmacologic treatments for pain (Heyward,
et al. 2018; Lin, et al., 2018; Volkow, & Collins, 2017), (c) counterdrug laws to diminish illicit
foreign and local drug supply and drug trafficking, (d) national prescription drug take-back,
(e) increase control of synthetic drugs from China (DOJ/DEA, 2017), and (f) drug enforcement
laws (DOJ/DEA, n.d.) may already have a positive impact in diminishing the number of young
adults with an OUD and possibly facing arrest. Implementation of childhood and adolescent
prevention approaches, for example, peer environment modification, and adverse childhood
experiences considerations (ACE; Dube, et al., 2003; Enoch, 2011; Hawkins, et al., 1992;
Volkow & Boyle, 2018) that address early risk factors is warranted.
On the contrary, funding should be made available for studies to expand knowledge on
the characteristics of those young adults who are not arrested, and to identify those who may be
at-risk for opioid use. Prevention interventions could then be implemented using the outcome of
these studies. NIH is already supporting initiatives to develop evidence-based interventions to
prevent opioid use disorder (NIH, 2019). Unraveling the details of an arrest (first time
arrest/repeat offender, opioid-related, charges, fines, sentencing, peer environment, ACE,
treatment status, MOUDs utilized) is essential in making strategic recommendations for practical
usage of this study’s findings on arrest history. Unfortunately, the specifics on arrest history
could not be examined in this study due to data limitations in the 2017 NSDUH.
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The analysis of employment data related to young adults with OUD show that the
employed young adult is less likely to use treatment when compared to the unemployed young
adult and those young adults not in the labor force. Employment is a modifiable characteristic.
However, employment modifications may not be simple for young adults, particularly if they do
not have higher education. The high prevalence of OUD among the employed should serve as an
indicator that employers, as stakeholders in their organizations, need to be educated on the
concerns of OUD and OUD treatment utilization. Employers can look beyond substance abuse
legislation and contribute to the treatment needs of their employees, by possibly influencing the
level of healthcare benefits included in employer sponsored insurance plans (removal of
substance use treatment limits, eliminating prior authorizations, lessening copayments), that limit
OUD treatment utilization. The Affordable Care Act requires most insurers to cover treatment
for SUD (NIOSH, 2019). Many insurers, however, may not cover all types of treatment for SUD
or provide the appropriate pharmacy benefits, as the ACA do not stipulate details in the SUD
treatment mandate (Abraham, et al., 2017). NIH, 2018 however, recommends eliminating priorauthorization requirements for MOUDs.
This study’s findings suggests that young adults with OUD and co-occurring mental illness
(over 89%) are not utilizing treatment for OUD. There is a need to integrate and coordinate
behavioral health care, as most young adults with OUD in the U.S. are shown to have a mild,
moderate, or serious mental illness. A 2015 forum of clinical and public health experts convened
at the Center for Mental Health and Addiction Policy Research at Johns Hopkins University and
recommended effective policy communication strategies to increase public support for policies
benefiting people with mental illness and SUD (McGinty, et al., 2018). Findings from this
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forum which may be beneficial for young adults with OUD and co-occurring conditions (mental
illness) include the use of sympathetic narratives (stories that humanize the experiences and
struggles of individuals with mental illness or SUD). The aim of this strategy is to allow
audiences to understand societal problems relating to mental illness and SUD and to increase
support for public policies that benefit people with mental illness and/or substance use disorders.
Additionally, the use of messaging which highlights structural barriers to treatment (inadequate
insurance coverage, limited access to provider, unavailability of evidence-based services) may
increase the public’s support for allocation of additional resources for mental illness and SUD
treatment. Funding opportunities continue to be awarded to address OUD in rural/nonmetropolitan areas (NIDA, 2017a). It is important to ensure that there is equity in OUD funding.
These practical strategies may positively influence treatment utilization and may be
valuable components to any drug treatment policy. The effectiveness of drug treatment policies
had been examined and findings indicated that policies could translate into public benefits
(Becker, et al., 2008; Reuter & Pollack, 2006).
Future Research
Collectively, this study’s findings are important contributions to the literature. However,
probing for deeper meaning into the significant associations (arrest history) with treatment
utilization is warranted. Individuals with no history of an arrest should be investigated,
Collection data on the characteristics of young adults with OUD, in longitudinal studies may
provide more meaningful results. Investigating ABM population characteristics among clearly
defined categories of the young adult population (not in college, varied sexual orientations,
mental and medical comorbidities, homeless, poverty status) is also needed. Technological
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advances should be developed to implement strategies to enhance treatment utilization among
young adults with OUD. It is also important to evaluate implementations of recommendations
made by institutions like NIH to determine whether they translate into increased treatment
utilization for OUD among young adults in the U.S. Additionally, future studies should the
differences between young adults who utilized treatment and young adults who do not utilize
treatment.
Summary and Conclusion
The low treatment utilization among young adults as evidenced in this study is startling.
Interventions that increase treatment utilization among young adults is essential. Recognizing
that young adults in the U.S. have higher treatment needs compared to older adults and the
highest OUD mortality rates it is crucial that future studies examine population characteristics
more deeply. MOUDs are available and have been reported to reduce mortality rates. This study
analyzed a subset of demographical, social, personal/family and community characteristics as
posited in the ABM to be associated with treatment utilization. A hierarchical binary logistic
regression model is used to analyze associations. The most important findings are that treatment
utilization is confirmed to be low among young adults with OUD in the U.S. In addition, the
model shows that having an arrest history means the young adult is more likely to utilize
treatment. Race/ethnicity, household size and employment status are significantly associated
with treatment utilization in the bivariate analysis. Significant population characteristics which
are modifiable are identified and practical strategies to increase treatment utilization for OUD
and to reduce the rates of OUD among young adults are recommended. Policies in place and
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strategies used to address OUD may not be efficient or appropriate for all segments of the young
adults’ population and needs to be evaluated.
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APPENDIX A
PERMISSION TO USE ANDERSEN BEHAVIORAL MODEL

RE: Requesting permission to use ABM
From: Ron Andersen
Sent: 2/25/2019 0:51
To: Marva Frederick
Cc: randerse@ucla.edu
Dear Marva,
You have my permission to use any of my works you use in your dissertation proposal or your
dissertation itself as long as the works are properly referenced. Your dissertation is considered a
publication so I think if you include tables or figures or a long text passage (a page or more?)
copied directly from the publication, you should probably check with the publishers as well. If
you significantly alter or revise the original material you can probably get by with a citation
explaining how you have altered the original material.
Best wishes for the successful completion of your dissertation.
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APPENDIX B
LEHMAN COLLEGE INSTITUTIONAL REVIEW BOARD (IRB) APPROVAL LETTER
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